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The global burden of cardiovascular disease (CVD) is on the increase with coronary artery disease 
(CAD) estimated to become the leading cause of mortality worldwide by 2020. The age of onset of 
this chronic disorder is on the decline, particularly in the South African Indian population. Indians in 
South Africa (SA) have a higher prevalence of premature CAD compared to other ethnic groups in 
SA. Coronary artery disease is a lifestyle and genetic disease, and the inheritance of genetic variation 
from one or both parents plays an important role in the risk of an individual developing CAD. Genetic 
and epigenetic studies are being explored as potential tools for therapeutic interventions against 
CVDs. The role of single nucleotide polymorphisms (SNP) in microRNAs (miR, miRNA) and 
molecules regulating epigenetic pathways remains poorly understood. This study investigated SNPs in 
candidate genes; methylenetetrahydrofolate reductase (MTHFR), sirtuin (SIRT) 1, miR-499, and miR-
146a; in young SA Indians with CAD.  
The study population included 106 SA Indian male CAD patients, 100 sex- and age-matched Indian, 
and 84 sex- and age-matched Black controls. The MTHFR, miR-146a, and miR-499 SNPs were 
investigated by PCR-RFLP, whilst a TaqMan SNP Genotyping assay assessed the SIRT1 SNPs. MiR-
146a expression was measured by qPCR and western blot was used to assess the expression of NF-
κB, IRAK-1, and TRAF-6. Interleukin (IL)-6 levels were analysed using an ELISA. All clinical 
parameters were obtained from pathology reports. 
Methylenetetrahydrofolate reductase is involved in folate metabolism and methylation pathways. The 
MTHFR rs1801133 has been associated with increased levels of homocysteine, a well known risk 
factor for CAD. Sirtuin 1, histone deacetylase, has been identified as a candidate molecule affecting 
the epigenetic mechanisms of CAD. Two common SNPs in the SIRT1 gene, rs7895833 and 
rs1467568, have been associated with several well-established risk factors for CAD. MicroRNAs 
(miRNAs) are small noncoding RNA molecules that inhibit messenger RNA (mRNA) translation or 
promoting mRNA degradation. MiR-499 and miR-146a are inflammatory-associated miRNAs. Two 
miRNA SNPs, miR-146a rs2910164 and miR-499 rs3746444, have been implicated in chronic 
inflammatory diseases.  
There was a significant association between the MTHFR variant (T) allele and CAD patients 
compared to Indian controls (p=0.0353, OR=2.105 95% CI 1.077–4.114). Indian controls presented 
with a higher frequency of the T allele compared to Black controls (7% vs. 2% respectively, p=0.0515 
OR=3.086 95% CI 0.9958–9.564). The variant allele for the two SIRT1 SNPs occurred more 
frequently in the total Indian group compared to the total Black population (rs1467568: 41% vs. 
18.5% respectively, p<0.0001, OR=3.190 95% CI 2.058-40943 and rs7895833: 41% vs. 22% 
xi 
 
respectively, p<0.0001, OR=2.466 95% CI 1.620–3.755). Indian controls presented with a higher 
frequency for both SNPs compared to Black controls (rs1467568: 40% vs. 18.5% respectively, 
p<0.0001, OR=2.996 95% CI 1.850–4.853 and rs7895833: 41% vs. 22% respectively, p<0.0001, 
OR=2.513 95% CI 1.578–4.004). No difference was seen in the distribution of both SNPs between 
CAD patients and either control group. The MTHFR and SIRT1 SNPs were not associated with any 
clinical parameters in CAD patients and controls. 
The miR-499 variant (G) allele was found at a higher frequency in the total Indian group (34%) 
compared to the total Black population (22%) (p=0.0070, OR=1.796 95% CI 1.182–2.730). Indian 
cases presented with higher frequency of the rs3746444 G allele compared to Indian controls (38% vs. 
29%, p=0.059, respectively). No differences in genotypic frequency for rs2910164 was found (GG: 45 
vs. 47 %, GC: 46 vs. 41 %, CC: 9 vs. 12 %) in controls and patients respectively (odds ratio=1.025; 
95 % confidence interval 0.6782–1.550; p=0.9164).  
The lowest levels of NF-κB and C-reactive protein (hsCRP) were found in patients with the 
homozygous C allele compared to the heterozygous GC and wildtype variants. Higher levels of miR-
499 targets, hsCRP and IL-6, were observed in CAD patients with the variant genotypes compared to 
those with the wild type genotypes (8.92±1.91 vs. 6.73±0.87 mg/L; p=0.299, 3.02±0.77 vs. 2.18±0.57 
pg/mL; p=0.381 respectively). A 6.25-fold increase in miR-146a levels was observed in CAD patients 
with the CC genotype (relative to controls and patients with the wildtype variant, p<0.0001). These 
(CC genotype) patients had significantly lower levels of miR-146a targets, IRAK-1 (0.38±0.02; 
p=0.0072) and TRAF-6 (0.44±0.02; p=0.0146).  
Taken together, this study provides the frequency distribution of the SNPs in four candidate genes for 
CAD in young South African Indians compared to Indian and Black controls. The frequency of 
variant alleles of rs1801133, rs3746444, rs7895833 and rs1467568 was greater in the Indian 
population compared to Black South Africans. Although no difference in frequency was observed for 
rs2010164, our results suggest a role for miR-146a in toll-like receptor (TLR) signalling via a 
negative feedback mechanism involving the attenuation of NF-κB by downregulation of IRAK-1 and 
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Thirty-eight million people worldwide die annually from non-communicable diseases (NCDs), mainly 
from cardiovascular diseases (CVDs). According to the World Health Organization (WHO), CVD 
kills approximately 17.5 million people each year, increasing to 25 million deaths annually in the next 
few years (Mendis, Armstrong et al. 2014). Coronary artery disease (CAD), which is the most 
important contributor to CVD, is expected to become the number one cause of mortality worldwide 
by 2020 (Levenson, Skerrett et al. 2002). Cardiovascular disease has been the leading cause of death 
in developed countries for most of the last century, however, the incidence of CAD in developing 
countries such as South Africa (SA) is on the rise (Okrainec, Banerjee et al. 2004). 
Evidence from mortality studies indicate that the global burden of CVDs is not shared equally across 
ethnic groups (Murray and Lopez 1997; Yusuf, Reddy et al. 2001). Indian populations worldwide 
have the highest prevalence of early-onset CAD compared to other ethnic groups (Rajeshwari, 
Nicklas et al. 2005; Khan 2013). Early-onset or premature CAD is defined as cardiac events occurring 
before the age of 55 in men and 65 in women, and before the age of 40 in its severe form (Rissam, 
Kishore et al. 2001). People of Indian ancestry in particular develop heart disease when they are 
younger than 40, a phenomenon unheard of in other populations (Sastry, Golla et al. 2011).  
The pattern with regard to early-onset CAD in the Indian population has been similar in various parts 
of the world for decades. In India, 25–40% of patients suffering from acute myocardial infarction 
(AMI) were below the age of 45 (Girija 1997). In Great Britain, AMI occurred in Indians younger 
than 40 years old — and the incidence was 10 times higher than the local Caucasian population 
(Rajadurai, Arokiasamy et al. 1992). Studies in Singapore reported that mortality due to CAD below 
30 years of age occurs 10 times more in the Indian population compared to the local Chinese (Hughes, 
Lun et al. 1990). In the Middle East, 80% of patients who experienced AMI were Indians below the 
age of 40, yet Indians account for approximately 10% of the population in this region. 
Angiographically, Indians have a 15 times higher rate of CAD than Chinese and 10 times higher rate 
than Malays below 40 years of age (Rissam, Kishore et al. 2001).  
In 1966, Wainwright reported a high incidence of CAD in SA Indians (Wainwright 1966). In 2006, 
reports showed that the highest death rates for CAD in SA occur in Indians, followed by mixed race, 
White, and Black (Norman, Schneider et al. 2006). This suggests that regardless of the number of 
generations of Indian immigrants who have lived in SA, there remains a differing pattern of CAD 




Coronary artery disease is a multifactorial disease that depends on the interaction between 
environmental risk factors and several predisposing genes (Andreassi, Botto et al. 2003). On a genetic 
basis, single nucleotide polymorphisms (SNP) in key genes may play a vital role in an individual's 
susceptibility and response to the disease. The role of SNPs in protein coding genes has been well 
investigated, but remains poorly understood in microRNAs (miRNAs; miRs) and molecules 
regulating epigenetic pathways.  
Epigenetics refers to mechanisms that regulate gene expression that do not involve alteration in DNA 
sequence. Three areas of epigenetics exist: DNA modification, histone modification, and RNA-based 
mechanisms (Pons, de Vries et al. 2009; Webster, Yan et al. 2013). The epigenetic pathways are 
complex and interconnected, and involve highly regulated molecules. Epigenetic research is relatively 
new but rapidly growing, and may provide novel insight into the complex mechanisms underlying 
CAD. 
Hyperhomocysteinaemia is a well-established risk factor for CAD. Methylenetetrahydrofolate 
reductase (MTHFR) reduces 5′,10′-methylenetetrahydrofolate to 5′-methyltetrahydrofolate, and is 
involved in remethylation of homocysteine to methionine, two important reactions involved in folate 
metabolism and methylation pathways. The common MTHFR C677T single nucleotide 
polymorphism (SNP) (rs1801133) has been associated with raised levels of homocysteine, a well 
known risk factor for CAD. 
Sirtuin (SIRT) 1, a class III histone deacetylase, has been identified as a candidate molecule affecting 
the epigenetic mechanisms of CVD. Previous studies have shown that some SIRT 1 SNPs are 
associated with inflammation, body mass index (BMI), type 2 diabetes (T2DM), blood pressure, and 
dyslipidemia, all of which are well-established risk factors for CAD (Finkel, Deng et al. 2009; Horio, 
Hayashi et al. 2011; Cui, Wang et al. 2012; Houtkooper, Pirinen et al. 2012). 
MicoRNAs are a class of small noncoding RNA molecules that negatively regulate gene expression of 
target genes by inhibiting messenger RNA (mRNA) translation or promoting mRNA degradation 
(Corsten, Dennert et al. 2010; Wang, Jiao et al. 2011). A single miR is able to regulate multiple target 
genes whereas one target gene may be regulated by various miRs (Li, Gao et al. 2011). MicroRNAs 
regulate most biological processes, therefore aberrant miR expression is likely to be implicated in 
several pathological conditions (Zhou, Rao et al. 2010; Yang, Chen et al. 2012). Genetic variation 
such as SNPs in miRs may affect their processing, expression and interaction with target genes (Li, 
Gao et al. 2011). Altered miR expression has been well investigated in various cancer types (Qiu, Hu 
et al. 2012; Li, Sheng et al. 2013), but miRs in cardiovascular disease is still an emerging field of 
research with very few studies focusing on coronary artery disease (Ono, Kuwabara et al. 2011). 
MicroRNA-499 and miR-146a are two of several miRs implicated in chronic inflammatory diseases 
such as CAD.  
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Several cytokines, including interleukin (IL)-17 receptor β (IL-17Rβ), IL-23a, IL-2β, IL-6, IL-2, IL-
18R, and IL-21 are well known targets of miR-499 (Yang, Chen et al. 2012; Hashemi, Eskandari-
Nasab et al. 2013). MicroRNA-499 has been implicated in inflammatory diseases such as rheumatoid 
arthritis (RA), and pulmonary tuberculosis (PTB) (Li, Wang et al. 2011; Yang, Chen et al. 2012). A 
common miR-499 A/G SNP (rs3746444) located within the stem region opposite the mature miR-499 
sequence, results in a change from an A:U pair to a G:U mismatch in the stem structure of miR-499 
(Wang, Tian et al. 2013). The variant G allele has a less stable secondary structure than the wildtype 
allele and directly affects the binding to target mRNAs and the miR maturation process, therefore 
altering protein expression and potentially contributing to disease susceptibility. 
miR-146a is involved in regulating the innate immune, and inflammatory response pathways (Zilahi, 
Tarr et al. 2011). A common G/C SNP (rs2910164) located within the crucial seed sequence of miR-
146a (Jazdzewski, Liyanarachchi et al. 2009) causes a change from a G:U pair to a mismatched C:U 
in the stem region and was shown to affect the expression of mature miR-146a (Xu, Zhu et al. 2008; 
Hung, Chang et al. 2012). Whether genetic variants of miR-146a confer differences in expression of 
miR-146a in CAD is unclear (Chatzikyriakidou, Voulgari et al. 2010; Yue, Wang et al. 2011; Hung, 
Chang et al. 2012). If such differences do occur, whether they are enough to produce significantly 
different regulatory effects on major mRNA targets remains unknown. 
The role of SNPs in inflammatory miRs such as miR-499 and miR-146a, and epigenetic regulators 
such as MTHFR and SIRT1 has not been described in SA Indians with CAD. Research identifying the 
role of genetic factors in determining susceptibility to CAD in the SA Indian population is needed. 
These genetic studies may contribute to a greater understanding of the genomic and epigenetic drivers 
of heterogeneity in individual responses to CAD, paving the way for personalised medical treatment 
(Mocumbi 2015). Discovery of genetic susceptibility loci may provide a clinically useful genetic risk-
prediction tool that will potentially allow identification of those at higher risk for CAD and early 
administration of therapeutics. 
Aims and objectives 
The overall aim of this study was to assess selected genetic and miRNA polymorphisms that may play 
a role in the susceptibility of early-onset CAD in South African Indians. 
The specific objectives of this study were designed to assess: 
(i) MTHFR rs1801133 (Chapter 3) 
(ii) SIRT1 rs1467568 and rs7895833 (Chapter 4) 
(iii) miR-499 rs3746444 (Chapter 5) 
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(iv) miR-146a rs2910164 (Chapter 6) 
Research questions 
 What are the frequencies of these SNPs in young SA Indians with CAD compared to Indian 
and Black controls? 
 Do these SNPs influence any clinical parameters? 
 Do the miR SNPs affect target gene expression? 
 Are these SNPs associated with CAD? 
 Do these molecules show any potential as biomarkers for therapeutic intervention against 
CAD? 
Study design 
A case-control study was designed to achieve the research objectives. Cases with angiographically 
documented CAD, that met the inclusion requirements, were enrolled into the study (Inkosi Albert 
Luthuli Central Hospital, Durban, South Africa). Control subjects were randomly selected, and those 
that met the inclusion criteria were recruited into this study. To be included into this study, cases 
needed to match the following criteria: Indian ancestry and unrelated, adults aged below 45 years and 
stable CAD confirmed on angiography. Exclusion criteria for patients were an acute coronary 
syndrome/ revascularisation procedure in the preceding three months, chronic renal or liver disease, 
malignancy and known active inflammatory or infectious disease. Indian and Black male controls that 
did not have heart disease were recruited. Inclusion criteria for controls were Indian/African ancestry, 
unrelated to one another, adult males below the age of 45 years and no known or suspected 
atherosclerotic vascular disease (Khan 2013).  
The present study was approved by the Biomedical Research Ethics Committee of KwaZulu-Natal 
(Ethics number: BE067/14), and conducted in accordance with the ethical principles described by the 
Declaration of Helsinki. After being well-informed about the study, all participants gave written 
informed consent. 
A total of 106* young SA Indian male CAD patients (mean age 37.5, range 24–45 years), 100* Indian 
male controls (mean age 37.5, range 28–45 years), and 84* Black male controls (mean age 36.4, range 
25–45) were enrolled in this study. Recruitment numbers were adequate for a 95% level of confidence 
and an 80% power to detect statistical differences. 
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2.1 An overview of coronary artery disease 
The coronary artery system is responsible for delivering oxygen- and nutrient-rich blood to the heart. 
Coronary artery disease (CAD), sometimes referred to as coronary heart disease (CHD), is a 
manifestation of atherosclerosis, which results in the coronary bed system failing to provide adequate 
blood supply to the heart due to the accumulation of atheromatous plaques within the walls of the 
coronary arteries (Figure 2.1) (Hansson 2005; Dzimiri, Wang et al. 2012). Atherosclerosis is a 
multifactorial disease characterised by chronic inflammation from initiation to progression, whereby 
immune and metabolic factors interact to propagate and activate arterial lesions (Hansson 2005). This 






Figure 2.1 A. An overview of the heart and coronary artery. B. Cross-section of the coronary artery 
showing plaque build-up and a blood clot, leading to dead heart muscle (NHLBI 2013) 
(httpwww.nhlbi.nih.govsiteswww.nhlbi.nih.govfilesimages_259) 
 
According to the American College of Cardiology and American Heart Association guidelines for 
coronary angiography, CAD is defined as the presence of ≥50% diameter stenosis in one or more 
major coronary artery and is classified as single, double, or triple-vessel disease; depending on the 
number of major coronary arteries affected (Scanlon P.J., Faxon D.P. et al. 1999). 
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2.2 Epidemiology of coronary artery disease 
The World Health Organisation (WHO) recently reported that noncommunicable diseases (NCDs) are 
the main cause of mortality worldwide, responsible for thirty-eight million annual deaths (World 
Health Organization, 2014). More than 17 million NCD deaths were due to cardiovascular disease 
(CVD) (46.2% of NCD deaths), and is projected to rise to 25 million in 2020 (Figure 2.2), surpassing 
infectious disease as the leading cause of mortality worldwide (Levenson, Skerrett et al. 2002; Fuster 
V and BB 2010). Coronary artery disease, the single most important contributor to CVD, is expected 
to become the number one cause of death worldwide by 2020 (Murray and Lopez 1997; Okrainec, 
Banerjee et al. 2004; Dahlöf 2010). By this time, developing countries are expected to contribute 85% 




Figure 2.2 The predicted change in the distribution of major causes of mortality worldwide 
(Levenson, Skerrett et al. 2002) 
 
 
2.3 Risk factors for coronary artery disease 
Extensive research has identified several factors that increase the risk of developing CAD. Some risk 
factors cannot be changed (non-modifiable risk factors), while others can be treated or changed 






2.3.1 Non-modifiable risk factors 
 
(a) Age  
Atherosclerosis is a cumulative process, beginning at a fairly young age. As the disease progresses 
with age, the risk of CAD increases (Jousilahti, Vartiainen et al. 1999). However, this pattern is 
changing as younger individuals are now presenting with early-onset CAD (Sharma M 2005; Khan 
2013). Early-onset or premature CAD is defined as cardiac events occurring before the age of 55 in 
men and 65 in women, and before the age of 40 in its severe form (Rissam, Kishore et al. 2001). 
People of Indian ancestry in particular develop heart disease when they are younger than 40, a 
phenomenon unheard of in other populations (Enas, V et al. 2007; Aggarwal, Aggarwal et al. 2012). 
 
(b) Gender 
Among middle-aged people, CAD is 2-5 times more common in men than in women, with a varying 
sex ratio between populations (Jousilahti, Vartiainen et al. 1999). Oestrogens provide a protective 
effect, but this is reduced once a woman reaches menopause, and her risk for CAD increases (Achari 
and Thakur 2004). The decrease in oestrogen production after menopause alters the female lipid 
profile, favouring a more atherogenic form by decreasing high-density lipoprotein (HDL) cholesterol 
and increasing low-density lipoprotein (LDL) cholesterol, total cholesterol, triglycerides (TG) , and 
lipoprotein(a) (Lp(a)) levels. In addition to having an effect on lipids, oestrogen may have 
cardioprotective effects via glucose metabolism as well as a direct effect on endothelial cell function. 
(Jousilahti, Vartiainen et al. 1999). The risk of CAD in women increases with the use of tobacco and 
oral contraceptives (Klein and Nathan 2003).  
 
A recent study involving more than 3000 British men explored the role of the Y chromosome in CAD 
(Charchar, Bloomer et al. 2012; Mearns 2012). They identified nine haplotypes, one of which 
(haplotype 1) had a 50% higher risk of CAD than the other Y chromosome lineages. Importantly, this 
association was independent of traditional cardiovascular risk factors such as body-mass index (BMI), 
blood pressure, lipids, diabetes, smoking, alcohol consumption, or circulating levels of C-reactive 
protein (CRP). Men who inherited haplotype 1 from their male ancestors had a downregulation of 
adaptive immunity and an upregulated inflammatory response compared to those who carried the 




A positive family history is a well known independent risk factor for CAD (Schächinger, Britten et al. 
1999; Sadeghi, Adnani et al. 2013). Coronary artery disease is a genetic disease, and the inheritance 
of genetic variation from one or both parents plays an important role in the risk of an individual 
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developing CAD. The associated risk further increases when first-degree relatives are affected at a 
younger age, with an odds ratio (OR) of 1.3 in individuals with relatives affected <55 years, to ORs of 
10 and greater in individuals with affected relatives <45 years (Sesso, Lee et al. 2001; Nasir, Michos 
et al. 2004).  
 
 
 Familial Hypercholesterolaemia 
 
Familial hypercholesterolaemia (FH) is associated with increased risk of CAD due to the genetically 
determined increased LDL cholesterol in these individuals (Narverud, Retterstol et al. 2014). The 
disorder is caused by the absence of or defective LDL receptors (LDLR) which occurs as a result of 
polymorphisms in the LDLR gene. The heterozygous form of this disorder occurs in 1 in 500 people 
who present with total cholesterol concentration in excess of 300 mg/dL. Approximately 5% of all 
patients who present with acute MI (AMI) before 60 years of age have heterozygous FH. The 
homozygous form of FH occurs in about 1 in 1 million individuals and presents with cholesterol 
levels ranging from 600-1000 mg/dL. These patients usually develop CAD before the age of 20 
(Crowther 2005). 
 
 (d) Ethnicity 
 
Ethnic and regional variations exist as risk factors for developing CAD (Figure 2.4) (Enas A Enas, 
Annamalai Senthilkumar et al. 2005; Dzimiri, Wang et al. 2012). People originating from the Indian 
subcontinent show unusually high incidence and mortality due to CAD. Asian Indians have the 
highest susceptibility in developing CAD, 3-4 times more than Caucasians, 6 times more than 




Figure 2.3 CAD mortality in Asian Indians compared with other ethnic groups (Enas A Enas, 
Annamalai Senthilkumar et al. 2005) 
 
Most South Africans of Indian ethnicity are descendants of indentured labourers who were brought to 
KwaZulu-Natal from India between 1860 and 1911 (Seedat 2005). Indians in India and South Africa 
(SA) are predisposed to the early onset of CAD, one to two decades earlier than other population 
groups, indicating a genetic link (Ranjith, Pegoraro et al. 2005; Sharma M 2005). In 1966, 
Wainwright reported a high incidence of CAD in South African Indians (Wainwright 1966). In 2006, 
reports still showed that the highest death rates for CAD in SA occur in Indians, followed by mixed 
race, White, and Black (Norman, Schneider et al. 2006). This suggests that regardless of the number 
of generations of Indian immigrants who have lived in SA, there remains a differing pattern of CAD 
mortality compared to the natives of the country, despite them sharing the same environment. (Lal 
2004). 
Indians develop CAD at a much younger age (younger than 40 years of age) compared to other 
ethnicities. Indian populations throughout the world have the highest mortality rate due to CAD 
compared with people of other ethnicities (Figure 1.4) (Enas A Enas, Annamalai Senthilkumar et al. 
2005). For decades, the pattern with regard to early-onset CAD in the Indian population has remained 
similar in various parts of the world. 
In India, 25-40% of patients suffering an AMI were below the age of 45 (Girija 1997). In Great 
Britain, AMI occurred in Indians younger than 40 years old – and the incidence was 10 times higher 
than the local Caucasian population (Rajadurai, Arokiasamy et al. 1992). Studies in Singapore 
reported mortality due to CAD below 30 years of age occurs 10 times more in the Indian population 
13 
 
compared to the local Chinese (Hughes, Lun et al. 1990). In the Middle East, 80% of patients who 
experienced AMI were Indians below the age of 40, yet Indians account for approximately 10% of the 
population in this region (Rissam, Banzal et al. ; Rissam, Kishore et al. 2001). 
Angiographically, Indians have a 15 times higher rate of CAD than Chinese and 10 times higher rate 
than Malays below 40 years of age (Rissam, Kishore et al. 2001). The disease is also much more 
severe in Indian cases. Compared to other ethnicities, young Indians often present with triple vessel 
disease with poor prognosis. Compared to Caucasians, Indians have a 3 times higher rate of re-
infarction and 2 times higher rate of mortality (Danaraj, Acker et al. 1959; Sharma, Kaul et al. 1990; 
Wilkinson, Sayer et al. 1996; Wild and McKeigue 1997). 
 
2.3.2 Modifiable risk factors 
(a) Diabetes mellitus and Metabolic syndrome 
 
Type 2 Diabetes mellitus (T2DM) is a multifactorial disease characterised by hyperglycaemia due to 
impaired insulin secretion, and may be acquired or inherited (Das and Elbein 2006). There is a strong 
genetic component in T2DM, where the risk of developing T2DM is substantially increased if the 
individual has first degree family with T2DM (Lin and Sun 2010; Olokoba, Obateru et al. 2012). An 
individual is further at risk for developing CAD if they are diabetic. Hyperglycaemia can lead to 
modification of macromolecules, by forming advanced glycation end products (AGE). By binding to 
surface receptors, AGE activate inflammatory pathways and upregulate the production of 
proinflammatory cytokines. The diabetic state also promotes oxidative stress, which perpetuates the 
inflammatory response (Libby, Ridker et al. 2002).  
 
Metabolic syndrome (MetS) is a complex disorder characterised by several integrated physiological, 
biochemical, clinical, and metabolic factors that directly increase risk for T2DM and CVD (Weng 
2005, Palmieri 2011). The exact mechanisms underlying the pathways of MetS are under 
investigation. The most important factors include genetics, epigenetics, aging, diet, obesity, and 
sedentary lifestyle (Kaur 2014). In addition to dyslipidaemia, hypertension, insulin resistance, and 
hyperglycaemia, the syndrome presents with a prothrombotic and proinflammatory state (Grundy 
2008). 
Various definitions of MetS have been proposed by different organisations over the past decade. The 
most common criteria for MetS currently used are from the WHO, the European Group for the study 
of Insulin Resistance (EGIR), the National Cholesterol Education Programme Adult Treatment Panel 
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III (NCEP ATP III), American Association of Clinical Endocrinologists (AACE), and the 
International Diabetes Federation (IDF) (Alberti, Eckel et al. 2009; Kaur 2014) (Table 2.1). 
 




WHO (1998) EGIR (1999) ATPIII 
(2001) 
AACE (2003) IDF (2005) 
Insulin 
resistance 
IGT, IFG, T2DM, or 
lowered insulin 
Sensitivitya 





plus any 2 of 
the following 
None, but 
any 3 of the 
following 5 
features 
IGT or IFG 
plus any of 
the following 






Men: waist-to hip 
ratio >0.90; 
women: waist-to-hip 
ratio >0.85 and/or 
BMI > 30 kg/m2 
WC ≥94 cm in 






in men or  
≥88 cm in 
women 
BMI ≥ 25 kg/m2 Increased WC 
(ethnic-specific) 
plus any 2 of 
the following 
Lipids TGs ≥150mg/dL 
and/or HDL <35 
mg/dL in men or 






















or on TGs Rx. 
HDL <40mg/dL 
in men or 
<50mg/dL in 
women or on 
HDL Rx 








or ≥85 mm Hg 
diastolic or on 
hypertension Rx 
















rate of >20mg/min 
or albumin: 
creatinine ratio of 
>30mg/g. 






aInsulin sensitivity measured under hyperinsulinaemic euglycaemic conditions, glucose uptake below 
lowest quartile for background population under investigation. 
bIn 2003, the American Diabetes Association (ADA) changed the criteria for IFG tolerance from >110mg/dl 
to >100mg/dl. 
cIncludes family history of T2DM, polycystic ovary syndrome, sedentary lifestyle, advancing age, and 
ethnic groups susceptible to T2DM. 
IFG: impaired fasting glucose; IGT: impaired glucose tolerance; BP: Blood pressure; Rx: receiving 
treatment; WC: waist circumference. 
 
A major concern with the WHO and NCEP ATP III definitions of MetS has been their applicability to 
different ethnic groups, especially with regards to obesity cut-offs. The IDF have taken this factor into 
consideration and has proposed a set of criteria with ethnic-specific cut-off, recognising that the 
relationship between theses values and the risk of T2DM and CVD differs amongst different ethnic 
groups (Kaur 2014). 
Several studies have been conducted worldwide on the prevalence of MetS across different ethnic 
groups (Al-Lawati, Mohammed et al. 2003; Park, Zhu et al. 2003; Misra, Wasir et al. 2005; Shiwaku, 
Nogi et al. 2005). The incidence of MetS ranges from <10% to as much as 84%, depending on region, 
environment, gender, age, and ethnicity of the study population. According to the IDF, one-quarter of 
the world’s population has MetS (Kaur 2014). People of Indian ethnicity have long been considered to 
be a “high-risk population” for both MetS and CVD, which has instigated a number of studies on 
Indians living in India and abroad (Tan, Ma et al. 2004; Misra, Wasir et al. 2005; Shah, Jonnalagadda 
et al. 2005). 
In a large population-based survey of the multi-ethnic Malaysian population, an overall MetS 
prevalence of 27.5% was observed, with marked differences across ethnicities. Compared to ethnic 
Malays, the prevalence of MetS was 16% lower among Chinese and 31% higher among Indians 
(Rampal, Mahadeva et al. 2012).  
Studies have shown increased thrombolysis in myocardial infarction (MI) time frame indicating 
impaired blood flow in coronary arteries even in the presence of angiographically normal coronary 
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arteries in MetS patients compared to patients without MetS, and is thought to play an important role 
in the pathogenesis of CAD (Aggarwal, Aggarwal et al. 2012). 
Metabolic syndrome and T2DM often present together, thereby significantly increasing the risk of 
CAD. Individuals with MetS have a 5-fold increased risk for T2DM and twice the risk of developing 
CVD compared to those without the syndrome (Grundy 2008).  
 
 
Figure 2.4 Indian Diabetes Risk Score (Mohan, Sandeep et al. 2007) 
 
The Indian Diabetes Risk Score (IDRS) makes use of clinical parameters such as age, WC, family 
history of diabetes, and physical activity to identify high-risk individuals (Figure 2.3). A score of ≥60 
has been found to be useful in predicting MetS and cardiovascular disease (Mohan, Sandeep et al. 




Cigarette smoking is considered one of the most important risk factors for vascular disease worldwide 
(Sadeghi, Adnani et al. 2013). Approximately 40% of all heart diseases have been related to smoking, 
and evidence suggests that smoking cessation is associated with a significant decrease in the risk of 
CAD (Teo, Ounpuu et al. 2006). Women who smoke have a similar risk of CAD as men, but more 
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than five times the risk of non-smoking women (Willett, Green et al. 1987; Klein and Nathan 2003). 
Passive smoking is an additional risk (Raupach, Schafer et al. 2006). Impaired vasodilatory function is 
an early manifestation of atherosclerosis. Cigarette smoking has shown to decrease nitric oxide (NO), 
the primary vasodilator of the endothelium. Cigarette smoking also increases inflammation, 
thrombosis, oxidation of LDL cholesterol, and oxidative stress, all of which impact atherosclerosis 
from endothelial dysfunction to acute clinical events. Smokers have a modified lipid profile, with 





Hypertension is a chronic medical condition in which arterial BP is constantly elevated, and is defined 
by a systolic BP (SBP) of ≥ 140mmHg or a diastolic BP (DBP) of ≥ 90mmHg (Rosendorff, Lackland 
et al. 2015). The condition is a contributing factor in MetS, and one of the leading preventable causes 
of premature CAD (Kearney, Whelton et al. 2005). Hypertension is considered a major independent 
risk factor for CAD. Each increase of 20mmHg in SBP (or 10mmHg in DBP) doubles the risk of a 
fatal coronary event (Rosendorff, Black et al. 2007).  
 
Hypertension causes an increased myocardial oxygen demand and decreased coronary blood flow, 
influencing vascular remodelling and atherosclerosis. The physical impact of hypertension can cause 
endothelial damage, characterised by an unfavourable balance between vasodilators (NO and 
prostaglandin E1) and vasoconstrictors (endothelin and angiotensin II). This is enhanced by the 
accumulation of reactive oxygen species (ROS) and other inflammatory mediators which promote 
atherosclerosis, thrombosis, and vascular occlusion (Olafiranye, Zizi et al. 2011).  
 
Associated metabolic disorders such as T2DM, insulin resistance, and obesity are strongly correlated 
with hypertension. For example, obese individuals (BMI of ≥30kg/m2) are more likely to be 
hypertensive than non-obese individuals. The mechanisms underlying the relationship between 
hypertension and obesity include sodium retention, activation of the renin-angiotensin-aldosterone 
system (RAAS), insulin resistance, and altered vascular function (Rosendorff, Lackland et al. 2015). 
 
More than 80% of patients with T2DM develop hypertension, and approximately 20% of hypertensive 
patients develop diabetes. The pathogenesis of hypertension and T2DM is multifactorial, but recent 
evidence points toward the presence of an important component dependent on a low-grade 




Activation of angiotensin II is a key component responsible for triggering vascular inflammation by 
inducing oxidative stress, resulting in up-regulation of pro-inflammatory transcription factors such as 
nuclear factor-kappa B (NF-κB). This, in turn, upregulates the generation of inflammatory mediators 
as well as increases the breakdown of NO, leading to endothelial dysfunction and vascular injury 
contributing to the progression of atherogenesis. Inflammatory markers (mainly interleukin (IL)-6, 
tumour necrosis factor-alpha (TNF-α), CRP, chemokines and adhesion molecules) are increased in 
patients with hypertension and metabolic disorders, and predict the development of CVD. (Savoia and 
Schiffrin 2007). In addition to angiotensin II, endothelin-1 also plays an important role in mediating 





Dyslipidaemia refers to an altered lipid profile characterised by increased levels of total cholesterol, 
LDL, TGs, and decreased HDL (Achari and Thakur 2004). High levels of LDL in circulation, in the 
presence of other risk factors including hypertension, T2DM, and smoking, causes oxidative 
modification of Lp(a). This induces the expression of adhesion molecules, chemokines, 
proinflammatory cytokines, and other inflammatory mediators. Apart from LDL, other lipoprotein 
molecules such as very low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL) 
are also susceptible to oxidative modification and therefore have atherogenic potential. Accumulation 
of lipid in the intima of coronary arteries form the necrotic core of the atherosclerotic plaque (Libby 
and Theroux 2005). High density lipoprotein serves a protective function against atherosclerosis, 
responsible for reverse cholesterol transport (RCT) and transport of antioxidant enzymes which 
degrade oxidised lipids and neutralise their proinflammatory effects (Libby, Ridker et al. 2002). 
(e) Diet, obesity, and physical inactivity 
 
An unhealthy diet comprising of high-fat foods, red meat, refined grains, and cholesterol-rich meals 
increases the risk of heart disease (Fung, Rimm et al. 2001). Interestingly, a study showed an inverse 
association between fruit and vegetable intake and the development of CVD events such as acute 
plaque rupture (Ignarro, Balestrieri et al. 2007).  
 
Obesity may be due to genetic inheritance or a result of unhealthy eating and sedentary lifestyle 
(Poirier, Giles et al. 2006), and is strongly associated with hypertension, endothelial dysfunction, and 
CAD (Lavie, Milani et al. 2009). Obesity is a predisposing factor for insulin resistance and diabetes, 
and contributes to dyslipidaemia. High levels of free fatty acids enter the liver and stimulate the 
production of triglyceride-rich VLDL. Elevated levels of VLDL can reduce HDL levels by enhancing 
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conversion of HDL to VLDL by cholesteryl ester transfer protein. Adipose tissue harbours resident 
macrophages which produce TNF-α and IL-6, which promote inflammation (Libby, Ridker et al. 
2002; Galkina and Ley 2009). 
Physical inactivity has been linked to CVD, whereas moderate exercise has been shown to prevent the 
incidence of atherosclerosis and CVD. Physical activity in combination with weight loss prevents and 
treats many established CAD risk factors such as hypertension, insulin resistance, increased 
triglycerides, LDL cholesterol and obesity (Thompson, Buchner et al. 2003). 
 
 
Coronary artery disease is a complex multifactorial disease characterised by the interaction of genetic, 
epigenetic, environmental, and lifestyle-associated factors. The risk factors above often occur in 
clusters and may build on one another, putting an individual at an even greater risk of CAD. In some 
cases, CAD develops without any of the classical risk factors. Studies have identified factors that may 
be responsible for this phenomenon, and classified them as “novel” risk factors (Wilson 2004). 
 
 
2.3.3 “Novel” risk factors 
 
(a) Excess homocysteine 
 
Elevated plasma homocysteine (Hcy) has been associated with risk of CAD. Levels of Hcy are 
determined by lifestyle as well as genetic predisposition. The methylenetetrahydrofolate reductase 
(MTHFR) C677T polymorphism is one of the strongest genetic predictors of Hcy (Mehlig, Leander et 
al. 2013). Increased Hcy can block the synthesis of NO, allowing the build up of plaque.  
 
Stühlinger et al. showed that Hcy post-transcriptionally inhibits dimethylarginine 
dimethylaminohydrolase (DDAH), the enzyme that degrades asymmetric dimethylarginine (ADMA), 
an endogenous inhibitor of NO synthase. This in turn causes the accumulation of ADMA and 
inhibition of NO synthesis (Stühlinger, Tsao et al. 2001). In addition, the sulfhydryl (SH) group of 
Hcy is oxidised to a disulphide bond in a reaction coupled to the formation of ROS such as hydrogen 
peroxide and superoxide. This increases the oxidative degradation of NO, inhibiting endothelium-
dependent NO-mediated dilation and favouring endothelial dysfunction (Carmel and Jacobsen 2001; 




The association between Hcy and CAD is furthermore due to promotion of smooth muscle cells into 
the intima, enhanced platelet aggregation, increased binding of Lp(a) to fibrin, production of free 
radicals, and formation of oxidised LDL (oxLDL) (Coffey, Crowder et al. 2003). 
 
The beneficial effects of Hcy-lowering therapy have been investigated. Although a large number of 
placebo-controlled clinical trials have been carried out to evaluate the efficacy of Hcy-lowering drugs, 
these interventions have not been proven to prevent the occurrence of cardiovascular events 
(Debreceni and Debreceni 2012). 
 
(b) C-reactive protein 
 
C-reactive protein is a plasma protein synthesised in the liver and is a sensitive marker of systemic 
inflammation. Experimental and clinical studies provide evidence of a direct contribution of CRP 
towards the pathogenesis of atherosclerosis. C-reactive protein binds to damaged cells and activates 
the complement system suggesting a potential proatherogenic role in foam cell formation and 
progression of atherosclerotic lesions. It also binds to degraded LDL and colocalizes with these 
particles in early atherosclerotic lesions. C-reactive protein is a powerful stimulator of tissue factor 
production by monocytes and this effect is increased in the presence of other inflammatory mediators 





Lipoprotein(a) is a LDL-like molecule that consists of an apolipoprotein B-100 (apo B-100) particle 
attached by a disulphide bridge to apolipoprotein A (apo A). Lipoprotein(a) contributes to 
atherosclerosis by causing endothelial dysfunction, promoting the proliferation of smooth muscle cells 
into the intima, and inducing the action of proinflammatory mediators. Furthermore, Lp(a) can 
undergo oxidative modification and scavenger uptake, resulting in foam cell formation 
(Malaguarnera, Vacante et al. 2013). 
 
2.4 Pathogenesis of coronary artery disease: Atherosclerosis – Roles of inflammation, 
endothelial perturbation and lipids 
 
Dyslipidaemia constitutes the major underlying basis of CAD. Increased lipid levels promote their 




The early stages of atherosclerosis is characterised by endothelial dysfunction which may be triggered 
by several factors including oxLDL, free radicals, elevated Hcy, and chronic systemic infection 





Figure 2.5 An overview of atherosclerosis in the coronary artery A. Endothelial dysfunction triggered 
mainly by exposure of the endothelium to oxLDL molecules attracts T-lymphocytes, monocytes, and 
platelets to the site of injury. B. LDL particles are engulfed by monocytes which thereafter transform 
into foam cells. Smooth muscle cells migrate from the media, and fatty streaks are formed. C. 
Accumulation of fatty streaks leads to a fibrous cap. The initial macrophages and monocytes begin to 
die and form a necrotic core covered by the fibrous cap. D. As the cap increases in size, the artery 
wall begins to expand until the plaque bulges into the vessel lumen. The fibrous cap eventually thins 
and ruptures, releasing the contents into the vessel lumen and resulting in thrombus formation. A large 
enough thrombus can cause luminal occlusion, causing myocardial infarction or stroke (Davis 2005). 
 
In an attempt to repair itself, the endothelium triggers the recruitment of T-lymphocytes, monocytes 
and platelets to the site of injury. When this reparative process fails, the permeability of the 
endothelium increases and lymphocytes and monocytes migrate deep into the intima, attracting LDL 
particles to the site. Activation of monocytes leads to cytokine-mediated progression of 
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atherosclerosis and oxidation of LDL (Figure 2.5 A.) (Crowther 2005; Davis 2005; Nazari-Jahantigh, 
Egea et al. 2014). 
 
Monocytes differentiate into macrophages and upregulate scavenger receptors and Toll-like receptors 
(TLRs) (Galkina and Ley 2009). Oxidised LDL is atherogenic and chemotactic for monocyte-
macrophages. The scavenger receptors mediate the uptake of oxLDL by the macrophages and results 
in foam cell formation, a process recently shown to be modulated by epigenetic mechanisms 
(Menghini, Stöhr et al. 2014). Macrophages become less mobile after the uptake of oxLDL, thereby 
promoting the accumulation of these lipid-rich cells in the intima. Toll-like receptor signalling leads 
to the release of cytokines, proteases, and vasoactive molecules (Figure 2.5 B.) (Crowther 2005; 
Hansson, Robertson et al. 2006; Nazari-Jahantigh, Egea et al. 2014). 
 
Many mediators of inflammation have been implicated in driving the process of atherosclerosis. 
These mediators include, but are not limited to, TNF-α and TNF-beta (β), interleukin IL-1β, IL-6, 
monocyte-colony stimulating factor (M-CSF), monocyte chemoattractant protein (MCP)-1, and IL-18 
(Crowther 2005). The functions of these inflammatory mediators range from angiogenesis to foam 
cell formation.  
 
Smooth muscle cells begin migrating from the media and accumulation of lipid-laden foam cells form 
fatty streaks, the earliest visible lesions of atherosclerosis (Crowther 2005). More lymphocytes are 
recruited to the lesion, thus contributing to the growing pool of effector cells that perpetuate the 
inflammatory response (Figure 2.5 C.)  (Chilton 2004).  
 
Progression of fatty streaks leads to a further attempt of endothelial repair, and a fibrous cap 
consisting of smooth muscle and collagen develops. The monocytes and macrophages from the 
original reaction die, resulting in the formation of a necrotic core covered by the fibrous cap. The 
fibrous cap and necrotic core, known as the atherosclerotic plaque, is the hallmark of established 
atherosclerosis (Figure 2.5 C.)  (Crowther 2005). 
 
Accumulation of lipid is required for the development and enlargement of the atherosclerotic plaque. 
An unstable plaque can rupture, releasing lipid fragments and cellular debris into the lumen and 
resulting in thrombus formation (Davis 2005). If large enough, the thrombus causes luminal 







2.5 Genetic variation in coronary artery disease 
 
Substantial progress has been made in understanding the genetic basis of human diseases since the 
completion of the human genome sequence. The genetic basis of CAD is especially important given 
that this is the leading cause of mortality worldwide. However, with the complexity of CAD, comes 
along several challenges – ranging from phenotypic and genetic heterogeneity to gene-gene and gene-
environment interactions (Table 2.2) (Kullo and Ding 2007).  
 
Table 2.2 Challenges in identifying genetic determinants of coronary heart disease reproduced from 




CHD can manifest as several clinical phenotypes, including chronic stable 
angina, acute coronary syndrome, MI, sudden cardiac death, and history of 
coronary revascularization. Measures of coronary atherosclerotic burden such 
as coronary artery calcium or angiographic coronary artery disease are 
objective and quantitative, unlike the dichotomous characterization (presence 
or absence) of a history of a cardiovascular event. Atherosclerotic disease 
burden and cardiovascular events such as myocardial infarction are distinct 
phenotypes, however, the latter being related more to plaque instability and 
rupture rather than plaque burden. 
Genetic 
heterogeneity 
Genetic heterogeneity is likely, given the multiple causal pathways that lead to 
CHD. For example, low plasma levels of HDL cholesterol can result from 
variation in genes from multiple metabolic pathways. Similarly, the transition 
from a stable coronary atherosclerotic plaque to an unstable inflamed plaque 
could be the result of genetic variation in multiple genes that participate in the 
inflammatory cascade and matrix degradation. 
Small gene effects A single genetic variant can constitute only a small proportion (e.g. 1–2%) of 
the total genetic contribution towards complex disease phenotypes, and an OR 
of 1.1–1.5 is typical for a susceptibility variant of a candidate gene (Risch 
2000). Uncovering such small effects requires large sample sizes, and 
recognition of this fact has motivated assembly of the so-called Biobanks in 




Identification of gene–gene and gene–environment interactions is essential for 
identification of genes responsible for complex diseases, and will require large 
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Most current genetic epidemiology studies of complex diseases such as CHD 
assume that common variants (i.e. minor allele frequency ≥5%) account for 
much of the susceptibility to the disease. Both common and rare variants, 
however, probably influence CHD susceptibility. To uncover rare variants that 
influence susceptibility to CHD, resequencing or very large sample sizes will 
be required. 
Abbreviation: CHD, coronary heart disease. 
 
Genetic variation occurs as a result of structural change(s) in the gene sequence due to modification of 
deoxyribonucleic acid (DNA) bases, producing different forms of the gene known as polymorphisms 
(Dzimiri, Wang et al. 2012). A single nucleotide polymorphism (SNP) is the most common type of 
genetic variation in the human genome (Xu, Zhu et al. 2008). As the name suggests, a SNP is a single 
base pair (bp) change in the DNA sequence. Each SNP is characterised by two alleles, together known 
as a genotype, with each allele existing on each homologous chromosome (Lanktree 2008). The 
frequency of SNPs within a particular gene varies from one population to another, and various SNPs 
have been associated with disease. 
 
2.5.1 Association studies: Identifying genes related to coronary artery disease – The candidate 
gene approach 
Association studies compare allele frequencies in cases and controls to assess the contribution of 
genetic variants to phenotypes of interest. Genetic variants occurring more frequently in cases than 
controls are considered to be associated with disease risk (Roberts and Stewart 2012).  
Genome-wide association studies (GWAS) search the entire genome for genetic variation. In contrast, 
the candidate gene approach focuses on association between a specific gene of interest and disease 
(Bampali, Mouzarou et al. 2014). 
Single nucleotide polymorphisms implicated in CAD are frequently found in genes controlling 
various mechanisms (e.g. lipid and glucose metabolism, inflammation, BP regulation, and vascular 






2.6 Epigenetics and coronary artery disease 
Epigenetics is a term used to refer to mechanisms that regulate gene expression that do not involve 
alteration in DNA sequence. The field of epigenetic research is relatively new but rapidly growing, 
and may provide novel insight into the complex mechanisms underlying CAD. A number of 
international initiatives have commenced, including the Human Epigenome Project (HEP) in 2003 
and the International Human Epigenome Consortium (IHEC) in 2010 (Webster, Yan et al. 2013).  
Three areas of epigenetics exist: DNA modification, histone modification, and ribonucleic acid 
(RNA)-based mechanisms (Pons, de Vries et al. 2009; Webster, Yan et al. 2013). The most 
investigated epigenetic mechanisms are DNA methylation and histone modification. RNA-based 
mechanisms such as microRNA (miRNA; miR) involvement are the newest branch of epigenetics. 
 
2.6.1 DNA Modification 
DNA methylation refers to the covalent methylation of cytosines located in CG dinucleotides (CpGs) 
catalyzed by DNA methyltransferases (DNMT). CpG sites are relatively rare in the genome but occur 
more regularly at the promoter regions of genes, and are collectively known as CpG islands (van Eijk, 
de Jong et al. 2012). DNA methylation controls gene expression by recruiting proteins involved in 
gene repression or by inhibiting the binding of transcription factor(s) to DNA. Increased methylation 
of CpG islands at 5’ end of a gene is associated with gene repression. The mechanisms for gene 
repression include interference with transcription factor binding or through the recruitment of 
repressors such as histone deacetylases (HDAC) (van Eijk, de Jong et al. 2012; Moore, Le et al. 
2013). 
S-adenosyl-methionine (AdoMet; SAM) is the main source of methyl groups for methylation 
reactions. After the transfer of methyl groups, S-adenosyl-Hcy (AdoHcy; SAH) is formed which can 
be hydrolysed to Hcy and adenosine. If Hcy accumulates (a well-known risk factor for CAD), 
AdoHcy also accumulates and increased AdoHcy is known to inhibit methyltransferases. Therefore 
Hcy levels may regulate global DNA methylation via AdoHcy (Handy, Castro et al. 2011). 
Methylenetetrahydrofolate reductase is an enzyme that catalyses the reduction of 5’,10’-
methylenetetrahydrofolate to 5’-methylenetetrahydrofolate; a major form of folate in plasma, and a 
carbon donor for the remethylation of Hcy to methionine (Kluijtmans and Whitehead 2001; Vasisht, 
Gulati et al. 2002). The enzyme is thus responsible for reducing levels of Hcy in the plasma. The TT 
genotype of the common MTHFR C677T SNP (rs1801133) has been associated with increased Hcy 




2.6.2 Histone Modification 
Genomic DNA is highly organised, and packed with histones to form chromatin. The nucleosome is 
the basic building block of chromatin, and consists of ~147bp of DNA wrapped around an octamer of 
histone proteins. Although core histones are tightly packed, their NH2-terminals can undergo 
modification by histone-modifying enzymes (Ling and Groop 2009). 
Histone modifications include methylation, phosphorylation, acetylation, and ubiquitination and are 
essential determinants of DNA transcription, replication, recombination, and chromosomal 
organisation (Schnabel, Baccarelli et al. 2012).  
The addition of acetyl groups by histone acetyl transferases (HAT) is thought to interfere with 
histone-DNA interactions, and allowing increased transcription factor access to DNA by “loosening” 
chromatin structure. Histone deacetylases (HDAC) remove acetyl groups and inhibit transcription 
factor access and transcription of genes (Mack 2008). 
Sirtuin (SIRT) 1, a class III HDAC, has been identified as a candidate molecule affecting the 
epigenetic mechanisms of CVD. Previous studies have shown that some SIRT 1 SNPs are associated 
with inflammation, BMI, diabetes, BP, and dyslipidaemia, all of which are well-established risk 
factors for CAD (Finkel, Deng et al. 2009; Horio, Hayashi et al. 2011; Cui, Wang et al. 2012; 
Houtkooper, Pirinen et al. 2012). 
2.6.3 Micro RNAs 
MicroRNAs are a class of small (~22 nucleotides in length), endogenous, single-stranded, non-coding 
RNA molecules that act by degrading or inhibiting the translation of messenger RNAs (mRNAs) 
(Jamaluddin, Weakly et al. 2011). These highly conserved molecules exert their function at post-
transcriptional level as negative regulators of gene expression (Jamaluddin, Weakly et al. 2011; 
Mittal, Gangwar et al. 2011; Raitoharju, Lyytikainen et al. 2011). Since their discovery in 1993 (Lee, 
Feinbaum et al. 1993), over 2500 human miRNAs have been described (Kozomara and Griffiths-
Jones 2014).  
Before publication of their discovery, experimentally confirmed miRNAs are given a name under a 







Table 2.3 Primary features of the miRNA nomenclature system adapted from (Wright and Bruford 
2011; Kozomara and Griffiths-Jones 2014) 
miRNA Nomenclature Example 
miRNA prefix “miR” is followed by a 
dash and a number, the latter 
indicates the order of naming 
miR-146 was named and likely 
discovered before miR-499 
Mature form of the miRNA Capitalised prefix “miR”  miR-499 
Precursor-miRNA and primary-
miRNA 
Referred to as pre- and pri- 
respectively, followed by an 
uncapitalised “mir” 
pre-mir-155 and pri-mir-155 
Closely related miRNAs miRNAs that have an almost 
identical sequence (differing by 
one or two nucleotides) are 
given an additional lower case 
lettered suffix 
miR-146a and miR-146b 
Sequences derived from the 5’ 
and 3’ arms of the hairpin 
precursor 
Are given an additional -5p and 
-3p respectively 
miR-100-5p and miR-100-3p 
miRNA species A three or four letter species 
prefix and numeric suffix 
hsa-miR-125 (Homo sapiens) 
mmu-miR-125 (Mus musculus) 
 
 
2.6.3.1 MicroRNA biogenesis and processing 
MicroRNAs are derived from longer primary RNA transcripts (pri-miRNAs). Processing begins in the 
nucleus, where the RNase III endonuclease Drosha and its binding partner DiGeorge syndrome 
chromosomal (or critical) gene 8 (DGCR8), cleaves the pri-miRNA into shorter (~70-85 nucleotides) 
precursor (pre-) miRNAs that consist of a stem-loop “hairpin-like” structure (Jamaluddin, Weakly et 
al. 2011). Precursor-miRNAs are then exported into the cytoplasm by exportin 5, and cleaved by 
DICER and its binding partner trans-activation response (TAR) binding protein (TARBP) into a 
miRNA duplex which is composed of a mature miRNA sequence (~22 nucleotides) and its 
complementary sequence miR*. The miRNA is loaded onto the RNA-induced silencing complex 
(RISC), and interacts with the 3’ untranslated region (UTR) of its target mRNA to control gene 
expression (Jamaluddin, Weakly et al. 2011) (Figure 2.6).  
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The seed sequence of the miRNA is a conserved region at positions 2-8 from the miRNA 5’-end and 
is important for target recognition. Binding of the miRNA and the target mRNA 3’ UTR determines 
the mechanism of mRNA-mediated gene regulation (Liu, Fortin et al. 2008; Lowery, Miller et al. 
2008; Jamaluddin, Weakly et al. 2011; Raitoharju, Lyytikainen et al. 2011; Rusca and Monticelli 
2011; Goldring 2012). Translation repression occurs when there is imperfect base pairing (mostly in 
animals) and perfect base pairing results in mRNA cleavage and degradation (mostly in plants) 
(Bartel 2004).  
 
Figure 2.6 Biogenesis and processing of miRNAs (Author’s own work) 
 
A single miRNA has target sites in hundreds of different genes, and more than 60% of protein-coding 
genes are conserved targets of miRNAs (Dai and Ahmed 2011). MicroRNAs are involved in almost 
all biological processes, including development, cell differentiation, proliferation, and apoptosis (Xu, 
Zhu et al. 2008).  
Aberrant miRNA regulation has been implicated in several disease conditions (Li, Chen et al. 2010). 
Recent studies reveal an important role of miRNAs in vascular biology and CVD, including CAD. 
Numerous miRNAs are highly expressed in the vasculature, and diseased vessels show dysregulated 




2.6.3.2 microRNAs in coronary artery disease 
The discovery of miRNAs as promising new biomarkers for CAD has ignited great expectations 
(Figure 2.7), and is being investigated as potential targets for therapeutic intervention. Having 
fulfilled several requirements of an ideal biomarker (stability in circulation, tissue- and pathology-
specific regulation as well as high sensitivity and specificity), miRNAs may even exceed protein-
based biomarkers (Schulte and Zeller 2015).  
 
Figure 2.7 Breakthrough discoveries in miRNA biology. Time line indicating seminal discoveries in 
miRNA biology with special focus on the cardiovascular field adapted from van Rooji 2011 (van 
Rooij 2011) 
Case-control studies have shown dysregulated miRNA levels in CAD patients compared with healthy 
controls (Contu, Latronico et al. 2010; Creemers, Tijsen et al. 2010; Fichtlscherer, De Rosa et al. 
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2010). The study of miRNAs in CVD is an emerging field of research and much is yet to be 
discovered. 
 
2.6.3.3 Single nucleotide polymorphisms in microRNA genes 
The binding of miRNA to mRNA is essential for regulating mRNA and protein expression. Given that 
miRNAs are so small in size and the critical role played by the seed sequence in miRNA-mRNA 
binding, a single nucleotide change in sequence could have a major consequence on miRNA-mRNA 
interaction and downstream expression (Jin and Lee 2013). Several miRNA SNPs were shown to 
affect miRNA expression and/or miRNA-mRNA interaction, and have been associated with human 
diseases (Chen, Song et al. 2008; Ardekani and Naeini 2010; Li, Chen et al. 2010). Single nucleotide 
polymorphisms in inflammatory-associated miRNAs such as miR-499 and miR-146a are of particular 
interest due to their implication in chronic inflammatory diseases. 
 
(a) miR-499 and rs3746444 
MicroRNA-499 acts by targeting several cytokines that play a role in the process of atherosclerosis. 
Interleukin-2, IL-2β, IL-6, IL-17, IL-17Rβ, IL-18, IL-21, and IL-23a are well-known targets of miR-
499 (Yang, Chen et al. 2012). A common miR-499 SNP, rs3746444, has been implicated in various 
inflammatory diseases (Li, Wang et al. 2011; Li, Gao et al. 2011; Hashemi, Eskandari-Nasab et al. 
2013). 
The miR-499 A/G SNP, located within the seed sequence of miR-499, results in a change from an 
A:U pair to a G:U mismatch (Figure 2.8). The variant (G) allele has a less stable secondary structure 





Figure 2.8 A common miR-499 SNP (rs3746444) located within the seed sequence results in a 
change from A-to-G (Author’s own work) 
 
In a Chinese Han population, Yang et al. found that rheumatoid arthritis (RA) patients who were 
carriers of the heterozygote rs3746444 variant had significantly higher erythrocyte sedimentation rate 
(ESR) and IL-6 compared to those with the homozygous wildtype. Their observations indicated that 
the SNP could be important in affecting the inflammatory response in RA patients (Yang, Chen et al. 
2012). These findings were supported by Hashemi et al. and El-Shal et al. who found that the variant 
allele was a risk factor for RA in Iranian and Egyptian populations respectively (El-Shal, Aly et al. 
2013; Hashemi, Eskandari-Nasab et al. 2013). Interestingly, The heterozygous variant of rs3746444 
was associated with a decreased risk for chronic obstructive pulmonary disease (COPD) (Li, Gao et 
al. 2011), but no association was found with systemic lupus erythematosus (SLE) in Chinese 
populations (Zhang, Yang et al. 2011). All four of these studies also investigated the miR-146a SNP, 
rs2910164, with no significant results being observed. 
Various genetic association studies have explored the role of rs3746444 in cancers including 
hepatocellular carcinoma (Akkız, Bayram et al. 2011), breast cancer (Catucci, Yang et al. 2010), and 
prostate cancer (George, Gangwar et al. 2011). Due to mixed and inconclusive results, a recent meta-
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analysis involving 7974 cases and 9404 controls was done to summarise and clarify the association 
between rs3746444 and cancer risk. The results showed that the miR-499 A/G SNP was associated 
with increased risk of cancer. Further subgroup analysis by ethnicity showed that association between 
rs3746444 and cancer susceptibility was significant in Asians, but not in Caucasians (Sun, Li et al. 
2014). 
To date, there have been only two published studies on the miR-499 rs3746444 with regards to CAD 
(Zhi, Wang et al. 2012; Xiong, Cho et al. 2014).  Recently, Zhi et al found that the GG genotype was 
associated with a 3.23-fold increased risk of CAD (Zhi, Wang et al. 2012). In contrast, Xiong et al 
found no association between rs3746444 and CAD in a Chinese Han population (Xiong, Cho et al. 
2014). 
(b) miR-146a and rs2910164 
MicroRNA-146a acts by targeting IL-1 receptor associated kinase (IRAK)-1 and TNF-α receptor 
associated factor (TRAF)-6, which act downstream of toll-like and IL-1 receptors (TIR) signalling 
pathway (Figure 2.9). This pathway occurs in a NF-κB-dependent manner (Chatzikyriakidou, 
Voulgari et al. 2010; Li, Chen et al. 2010), and is involved in regulating inflammation (Roldán, 
Arroyo et al. 2014). 
 
Figure 2.9 The role of IRAK-1 and TRAF-6 (targets of miR-146a) in the TIR signalling pathway 




Under conditions of hyperlipidaemia, TLRs participate in regulating atherosclerosis and inducing the 
production of proinflammatory cytokines (Galkina and Ley 2009). Prior to activation of the receptor, 
myeloid differentiation primary response gene 88 (MyD88), TRAF-1 and IRAK-4 are found in the 
cytosol. IRAK-1 is found in association with toll interacting protein (TOLLIP), an inhibitory adaptor 
protein (Gottipati, Rao et al. 2008). Upon binding of the ligand to the TIR, MyD88 is rapidly recruited 
to the receptor via interaction of the death domains of both molecules (Takeda and Akira 2004; 
Flannery and Bowie 2010). IRAK-1 is recruited to the receptor complex and binds to MyD88, which 
brings it closer to IRAK-4 (O'Neill 2008). This results in the phosphorylation of IRAK-1 by IRAK-4, 
resulting in the activation of IRAK-1 kinase activity and formation of hyper-phosphorylated IRAK-1 
by auto-phosphorylation.  
 
MyD88 and TOLLIP only bind to non-phosphorylated IRAK-1, thus upon phosphorylation IRAK-1 is 
released from the receptor complex and binds to TRAF-6 (Flannery and Bowie 2010). IRAK-1 and 
TRAF-6 interact via multiple domains, including their death domains and C-terminals (Gottipati, Rao 
et al. 2008). The IRAK-1/TRAF-6 complex dissociates from the receptor complex and interacts with a 
performed complex made up of transforming growth factor-beta (TGF-β)-activated kinase (TAK) 1, 
TGF-β-activated kinase-binding protein (TAB) 1, and TAB2 (Janssens and Beyaert 2003). This leads 
to the phosphorylation of TAB2 and TAK1, and further translocation into the cytosol.  
 
IRAK-1 remains at the membrane and is degraded by a ubiquitin-dependent mechanism, while 
TRAF-6, TAK1, TAB1 and TAB2 associate with ubiquitin ligases (Muroi and Tanamoto 2012). This 
causes the ubiquitination of TRAF-6, an important step required for activating the kinase activity of 
TAK1. The inhibitor of kappa B (IκK) complex (consisting of IκK-α, IκK-β, and IκK-γ) is 
phosphorylated by TAK1. The complex in turn phosphorylates inhibitor of NF-κB kinase subunit beta 
(IκB), resulting in its degradation. This allows the translocation of NF-κB into the nucleus and 
subsequent binding to specific promoter sequences, activating inflammatory genes (Chung, Park et al. 












Several SNPs have been identified in the miR-146a gene. A common SNP; rs2910164, has been 
widely studied in RA, tuberculosis (TB), and several cancers (Chatzikyriakidou, Voulgari et al. 2010; 
Li, Wang et al. 2011; Yue, Wang et al. 2011). Few studies have focused on CAD, especially in the 
Indian population. 
 
The G-to-C SNP (rs2910164) has been identified in the crucial seed region of the miR-146a gene 
(Jazdzewski, Liyanarachchi et al. 2009) (Figure 2.10), causing a change from a G:U pair to a C:U 
mismatch (Hung, Chang et al. 2012). This SNP is seems to affect the expression of mature miR-146a, 
however whether the G- or C-variant causes a decrease/increase in mature miR-146a remains 




Figure 2.10 Schematic representation of the miR-146a loci and the sequence of mature miR-146a on 
human chromosome 5 (Li, Chen et al. 2010) 
 
Although observing no association between rs2910164 and RA, Chatzikyriakidou et al. reported 
increased miR-146a expression in synovial fibroblasts, synovial tissue, and PBMCs from RA patients 
(Chatzikyriakidou, Voulgari et al. 2010). A similar finding was observed by Pauley et al. who found 
an increased expression of miR-146a in PBMCs from RA patients, coupled with similar expression of 
IRAK-1 and TRAF-6 in both patients and controls despite the increased expression of miR-146a in 
RA patients (Pauley, Satoh et al. 2008).  
In contrast to increased expression of miR-146a in RA patients, there have been reports of decreased 
miR-146a expression in patients with SLE. A recent study reported that miR-146a is intrinsically 
underexpressed in SLE patients, and miR-146a levels correlated negatively with SLE activity (Tang, 
Luo et al. 2009). This is interesting as both RA and SLE are autoimmune diseases. The precise 
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mechanism for the difference in miR-146a expression among the different diseases remains unknown. 
The overall cytokine profiles in these disease may account for these patterns (Li, Chen et al. 2010). 
The effect of rs2910164 on miR-146a expression is heterogeneous across different cancers (Hung, 
Chang et al. 2012). Yue et al. showed that the G-variant is associated with decreased expression of 
mature miR-146a and increased risk for cervical cancer (Yue, Wang et al. 2011), while Shen et al. 
demonstrated that the C-variant caused increased expression of mature mir-146a and increased the 
risk of an early onset familial breast and ovarian cancers (Shen, Ambrosone et al. 2008). Hung et al. 
observed increased expression of miR-146a in oral squamous cell carcinoma (OSCC) patients with 
the rs2910164 C variant (Hung, Chang et al. 2012). Xu et al. showed that the G-variant results in an 
increase in mature miR-146a, and a two-fold increase in susceptibility to liver cancer (Xu, Zhu et al. 
2008). The C-variant caused a decrease in miR-146a, and decreased risk of prostate carcinoma (Xu, 
Feng et al. 2010). In 2008, Jazdzewski et al. observed a 1.8-fold decrease in miR-146a with the C-
variant compared to the G-variant, and that the GC genotype is associated with an increased risk of 
papillary thyroid carcinoma (Jazdzewski, Murray et al. 2008).  
In 2011, Zilahi et al. measured the expression of miR-146a, and its target genes, IRAK-1 and TRAF-6 
in the PBMCs of patients with Sjögren’s syndrome and healthy controls (Zilahi, Tarr et al. 2011). 
Their results showed that while both miR-146a and TRAF-6 were significantly overexpressed in 
patients with Sjögren’s syndrome, the expression of IRAK-1 was significantly decreased. They 
suggested that as IRAK-1 is regarded an important gene in the pathogenesis of SLE, TRAF-6 could be 
a biomarker specific to Sjögren’s syndrome. 
Li et al. investigated the miR-146a rs2910164 and susceptibility to TB in the Chinese Tibetan and 
Han population (Li, Wang et al. 2011). They observed that the G allele carriers are prone to develop 
TB in the Tibetan but not Han individuals. This suggests that the miR-146a rs2910164 variants play 
different roles in the two populations. 
There are limited studies focusing on rs2910164 and the role of miR-146a in CVD. Expression of 
miR-146a was upregulated in the PBMCs of patients with acute coronary syndrome (ACS), including 
stable angina and AMI. The overexpression of miR-146a correlated with increased expression of 
proinflammatory cytokines, a critical factor in atherosclerosis (Jamaluddin, Weakly et al. 2011).  
In a more recent study recent study investigating the possible relationship between rs2910164 and 
ACS in a Chinese population found that the GC genotype was significantly associated with decreased 
risk of ACS. Further analysis showed that the decreased risk was predominant in male subjects with 
body mass index more than 24 kg/m2, and in hypertensive subjects (Huang, Lv et al. 2015). 
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Xiong et al. evaluated the influence of rs2910164 on individual risk for CAD in a Chinese population. 
The CC genotype was associated with increased susceptibility of developing CAD compared to 
individuals with the GG and GC genotypes. This increased risk was speculated to be due to the 
influence of the polymorphism on miR-146a expression levels. Individuals carrying the C allele 
exhibited a higher expression of mature miR-146a (Xiong, Cho et al. 2014). 
The Tampere Vascular Study found an increase in miR-146a expression in atherosclerotic arteries 
compared to control arteries (Raitoharju, Lyytikainen et al. 2011). This highlights the potential of 
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Methylenetetrahydrofolate reductase (MTHFR) reduces 5′,10′-methylenetetrahydrofolate to 5′-
methyltetrahydrofolate, and is involved in remethylation of homocysteine to methionine, two 
important reactions involved in folate metabolism and methylation pathways. The common MTHFR 
C677T single nucleotide polymorphism (SNP) (rs1801133) has been associated with raised levels of 
homocysteine, a well known risk factor for coronary artery disease (CAD). CAD is a major cause of 
mortality worldwide. The age of onset of this chronic disorder is on the decline, particularly in the 
Indian population. Indians in South Africa (SA) have a higher prevalence of premature CAD 
compared to Black South Africans. The MTHFR C677T SNP has not been investigated in the SA 
Indian population. The present study therefore investigated the MTHFR C677T SNP in young SA 
Indian males with CAD compared to young Indian and Black male controls. A total of 290 subjects 
were recruited into this study which included 106 CAD patients (diagnosed on angiography, mean age 
37.5, range 24–45 years), 100 Indian male controls (mean age 37.5, range 28–45 years), and 84 Black 
male controls (mean age 36.4, range 25–45). Polymerase chain reaction (PCR) followed by restriction 
fragment length polymorphism (RFLP) was used to genotype CAD patients and healthy controls. 
Data for clinical markers were obtained from pathology reports. There was a significant association 
between the 677MTHFR variant (T) allele and CAD patients compared to the healthy Indian controls 
(p=0.0353, OR=2.105 95% CI 1.077–4.114). Indian controls presented with a higher frequency of the 
variant allele compared to Black controls (7% vs. 2% respectively, p = 0.0515 OR = 3.086 95% CI 
0.9958–9.564). The MTHFR C677T SNP did not influence levels of total cholesterol, LDL, HDL, 
triglycerides, fasting glucose, fasting insulin, HbA1c or hsCRP. The higher frequency of the MTHFR 
677 variant allele in South African Indians may be a contributing factor to the higher risk profile for 
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Methylenetetrahydrofolate reductase (MTHFR) is an enzyme that catalyses the reduction of 5′,10′-
methylenetetrahydrofolate to 5′-methyltetrahydrofolate; a major form of folate in plasma, and a 
carbon donor for the remethylation of homocysteine to methionine (Kluijtmans and Whitehead 2001; 
Vasisht, Gulati et al. 2002). The enzyme is therefore responsible for reducing levels of homocysteine 
in the plasma. 
 
The 2.2kb long MTHFR gene is located on the short arm of chromosome 1 at 1p36.3. A common SNP 
at position 677 of the MTHFR gene (rs1801133) in which a cytosine is converted to thymine, results 
in the substitution of a alanine residue to valine in the enzyme (Anderson, King et al. 1997). The 
encoded protein has reduced activity at 37°C and higher, and thus the C677T SNP is termed 
“thermolabile” (Vasisht, Gulati et al. 2002). The MTHFR 677 TT genotype has been linked to 
increased plasma homocysteine levels (Anderson, King et al. 1997; Clarke, Bennett et al. 2012; 
Mehlig, Leander et al. 2013; Nienaber-Rousseau, Ellis et al. 2013).  
 
Elevated total plasma homocysteine (tHcy) is an established risk factor for CAD that appears to occur 
independently of other conventional risk factors (Doshi, McDowell et al. 2002). There are several 
proposed mechanisms to explain the association between homocysteine and CAD, including 
endothelial cell dysfunction, enhanced platelet aggregation, production of free radicals, and 
stimulation of oxidation of low-density lipoprotein (LDL) (Stanger, Semmelrock et al. 2002; Coffey, 
Crowder et al. 2003). 
 
Dietary intake and status of folate, and to a lesser extent the status of vitamins B2, B6, and B12, are 
classical determinants of plasma homocysteine (Muskiet 2005). Oral folate supplements can 
effectively lower plasma homocysteine levels (Clarke 1998). The metabolism of homocysteine and 
folate are interrelated, and increasing folate intake enhances remethylation of homocysteine. A daily 
dose of 0.4-0.5 mg of folate is reported to reduce tHcy by 25% (Doshi, McDowell et al. 2002). This 
has led to the suggestion that folate supplementation may reduce the risk of CAD and other vascular-
related disease by reducing tHcy. 
 
Coronary artery disease is a multifactorial disease that depends on the interaction between 
environmental risk factors and several predisposing genes (Andreassi, Botto et al. 2003). On a genetic 
basis, SNPs in key genes may play a vital role in an individual’s susceptibility and response to the 




Although the relationship between the MTHFR C677T variant and risk of CAD is not yet fully 
understood, the SNP may be important in disease mechanisms underlying CAD due to its influence on 
tHcy levels. The role of the MTHFR C677T SNP in CAD has been investigated across a range of 
ethnic groups (Gudnason, Stansbie et al. 1998; Friso, Girelli et al. 2002; Sun, Xu et al. 2005). Indian 
populations worldwide have the highest prevalence of early-onset CAD compared to other ethnic 
groups (Rajeshwari, Nicklas et al. 2005). Early-onset or premature CAD is defined as cardiac events 
occurring before the age of 55 in men and 65 in women, and before the age of 40 in its severe form 
(Rissam, Kishore et al. 2001).  
 
People of Indian ancestry in particular develop heart disease when they younger than 40, a 
phenomenon unheard of in other populations (Sastry, Golla et al. 2011). The pattern with regards to 
early-onset CAD in the Indian population is similar in various parts of the world. In India, 25-40% of 
patients suffering from acute myocardial infarction (AMI) were below the age of 45 (Girija 1997). In 
Great Britain, AMI occurred in Indians younger than 40 years old – and the incidence was 10 times 
higher than the local Caucasian population (Rajadurai, Arokiasamy et al. 1992). Studies in Singapore 
reported mortality due to CAD below 30 years of age occurs 10 times more in the Indian population 
compared to the local Chinese (Hughes, Lun et al. 1990). In the Middle East, 80% of patients who 
experienced AMI were Indians below the age of 40, yet Indians account for approximately 10% of the 
population in this region (Rissam, Banzal et al. ; Rissam, Kishore et al. 2001). Angiographically, 
Indians have a 15 times higher rate of CAD than Chinese and 10 times higher rate than Malays below 
40 years of age (Rissam, Kishore et al. 2001).  
 
The occurrence of CAD is on the rise in developing countries such as South Africa. Most South 
African Indians are descendants of indentured labourers who were brought to KwaZulu-Natal from 
India between 1860 and 1911 (Seedat 2005). Indians in India and South Africa are predisposed to the 
early onset of CAD, one to two decades earlier than other population groups, indicating a genetic link 
(Ranjith, Pegoraro et al. 2005; Sharma M 2005). In 1966, Wainwright reported a high incidence of 
early-onset CAD in South African Indians (Wainwright 1966). In 2006, reports still showed that the 
highest death rates for early-onset CAD in South Africa occur in Indians, followed by mixed race, 
White, and Black (Norman, Schneider et al. 2006). This suggests that regardless of the number of 
generations of Indian immigrants who have lived in South Africa, there remains a differing pattern of 
early-onset CAD mortality compared to the natives of the country, despite them sharing the same 
environment and to some extent similar diets and cultural habits (Lal 2004). There is currently no 
literature available on South African Indians with regard to the MTHFR C677T SNP. We set out to 






2.1. Patient recruitment and sample collection 
A total of 106 young SA Indian male CAD patients (mean age 37.5, range 24–45 years), 100 Indian 
male controls (mean age 37.5, range 28–45 years), and 84 Black male controls (mean age 36.4, range 
25–45) were enrolled following institutional ethical approval (BE067/14). A full pathology report of 
clinical markers was assessed by routine laboratory testing at Global Clinical and Viral Laboratory 
(Amanzimtoti, South Africa) — a South African National Accreditation System (SANAS) certified 
laboratory. The following parameters were tested: Haematology (Roche Sysmex 1800XT), Chemistry 
(Beckman Coulter DXC600), Endocrinology and hsCRP (Siemens Centaur XP), Serology (BD 
Biosciences FACS Calibur) as per international standards to obtain levels of total cholesterol, HDL, 
LDL, triglycerides, fasting glucose, 2 h glucose, fasting insulin, glycosylated haemoglobin, sodium, 
potassium, bicarbonate, chloride, urea, creatinine, glomerular filtration rate, cluster of differentiation 
(CD) 4 count, CD8 count, CD45 count and CD3 count. The physical measurements of weight, height, 
abdominal circumference, waist circumference, and patient history were conducted by the clinician. 
The inclusion criteria for young CAD patients were: Indian ancestry and unrelated, adults aged b45 
years, and stable CAD confirmed on angiography. Exclusion criteria for patients were an acute 
coronary syndrome/ revascularisation procedure in the preceding three months, chronic renal or liver 
disease, malignancy and known active inflammatory or infectious disease. Indian and Black male 
controls who did not have heart disease were recruited. Inclusion criteria for controls were 
Indian/African ancestry, unrelated to one another, adult males below the age of 45 years and no 
known or suspected atherosclerotic vascular disease. For control subjects, a blood sample was drawn 
and in addition an exercise electrocardiogram (ECG) was recorded in order to exclude heart disease. 
The exclusion criteria for controls were as for cases, and included the following: symptoms or clinical 
evidence of atherosclerotic vascular disease i.e. CAD, stroke/carotid disease or peripheral vascular 
disease, evidence of ischaemia/infarction on 12 lead resting ECG or evidence of ischaemia on 
treadmill exercise stress testing done to predict maximum heart rate. A positive family history was 
recorded if any first degree relative (father, mother, brother or sister) had CAD (Table 2). 
2.2. DNA extraction 
Genomic DNA was extracted from the whole blood sample of each patient and control according to 
the method described by Sambrook et al. 2001 (Sambrook and Russell 2001). Cells were transferred 
to 600μl lysis buffer (0.5% sodium dodecyl sulphate (SDS), 150mM NaCl, 10mM 
ethylenediaminetetra-acetic acid (EDTA), 10mM Tris-HCl (pH 8.0)). To this, RNase A (100μg/mL; 
DNase-free) was added to the solution and incubated (37°C, 1h). Proteinase K (200μg/mL) was then 
added and incubated (3h, 50°C). Protein contaminants were then precipitated by adding 5mM 0.1% 
potassium acetate before centrifugation (5000×g; 15min). Supernatants containing genomic DNA 
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were transferred to fresh tubes and extracted with 100% isopropanol on ice and thereafter washed 
with 70% ethanol. DNA samples were dissolved in 10mM Tris and 0.1mM EDTA (pH 7.4, 4°C). 
DNA concentration was determined using the NanoDrop 2000 spectrophotometer, and all samples 
were standardised to a concentration of 10ng/μl. 
2.3. Genotyping 
A 198 bp amplicon was obtained by polymerase chain reaction (PCR) amplification of the genomic 
DNA using 40ρmol of each primer (forward: 5′-TGAAGGAGAAGGTGTCTGGGGGA-3′ and 
reverse: 5′-AGGACGGTGCGGTGAGAGTG-3′), 200μM of each dNTP, 2.5mM MgCl2, 1× Green 
GoTaq Flexi buffer, 0.2U GoTaq DNA polymerase (Promega) and 30ng genomic DNA template. 
PCR was performed under the following cycling conditions: 95°C for 5min (initial denaturation), 
followed by 95°C for 1min, 59°C for 1min (annealing), 72°C for 2min, and 72°C for 7min (final 
extension), for a total of 35 cycles. PCR products were electrophoresed on agarose gel (1.8%, 
0.5mg/mL ethidium bromide) and visualised using the Uvitech image documentation system (Uvitech 
Alliance 2.7). 
PCR-RFLP was used to determine the MTHRF C677T genotypes. PCR products were subjected to 
overnight restriction digestion by HinfI (5 Units) at 37°C. Restriction products were electrophoresed 
on agarose gel (3%, 0.5mg/mL ethidium bromide) and visualised as was the PCR product. Presence of 
the wild-type C-allele resulted in no cleavage of the PCR product. Heterozygote C677T yielded three 
fragments of 198 bp, 175 bp, and 23 bp. Homozygote C677T yielded two fragments of 175 bp and 23 
bp (Figure 3.1). 
2.4. Statistical analysis 
The Hardy–Weinberg equilibrium was used to test for deviation of allele/genotype frequency. All 
other statistical analysis was performed with Graphpad prism software (version 5.0). Allele and 
genotype frequencies were calculated using the Fisher's exact and Chi square tests, respectively. 
Comparisons for clinical characteristics amongst CAD patients, Indian controls, and Black controls 
were done by performing a one-way ANOVA. Characteristics of CAD patients according to genotype 
was analysed by a non-parametric T-test. Results are expressed as mean ± standard error. A p value 








The MTHFR C677T SNP was investigated using PCR-RFLP. The genotype distribution complied 
with the Hardy–Weinberg equilibrium in Indian and Black controls (Chi squared p=0.753, and 
p=0.975 respectively; Table 3.1).  
There was significant association between the 677 MTHFR variant (T) allele and CAD patients 
compared to the healthy Indian controls (p=0.0353, OR =2.105 95% CI 1.077–4.114; Table 3.1). 
Indian controls presented with a higher frequency of the variant allele compared to Black controls 
(7% vs. 2% respectively, p=0.0515 OR = 3.086 95% CI 0.9958–9.564; Table 3.1). 
 
 
Figure 3.1HinfI-restricted MTHFR gene fragments. Lane 1: PCR amplicon product, Lane 2 and 3: CT 

















Table 3.1 Frequency of MTHFR C677T genotypes and alleles in SA Indian CAD patients and 
controls (Indian and Black). 
 
 South African Indians South African 
Blacks 






Genotypes    
CC n (%) 79 (74.5) 86 (86) 80 (95) 
CT n (%) 25 (23.5) 14 (14) 4 (5) 
TT n (%) 2 (2) 0 (0) 0 (0) 
Alleles    
C n (%) 183 (86) 186 (93) 164 (98) 
T n (%) 29 (14) 14 (7) 4 (2) 
HWE P value  0.753 0.975 
p-value 0.0353a 0.0515b  
 
Fisher’s exact test for heterogeneity between a healthy SA Indian and coronary artery disease (CAD) 
patients and b healthy SA Black and healthy SA Indian 
HWE: Hardy-Weinberg equilibrium 
 
As expected, CAD patients presented with more conventional risk factors (diabetes, hypertension, 












Table 3.2 Demographics and clinical parameters for CAD patients, Indian, and Black controls 







Prediabetic/diabetic n (%) 63 (59) 39 (39) 12 (14) 0.0036a 
0.0002b 
Hypertensive n (%) 44 (42) 22 (22) 2 (2) 0.0029a 
p<0.0001b 
Positive family history of 
CAD (%) 
85 47 1 p<0.0001a 
p<0.0001b 
Smokers/Ex-smokers 96 65 43 p<0.0001a 
0.0715b Non-smokers 10 35 41 
Age (years) 37.6 37.5 36.4 0.9256a 
0.1080b 
BMI (kg/m2) 28.15±0.45 26.31±0.55 28.95±0.51 0.0104a 
0.6275b 
Laboratory parameters     
Total cholesterol (mmol/L) 5.35±0.18 5.48±0.10 4.2±0.11 0.5362a 
p<0.0001b 
LDL-cholesterol (mmol/L) 3.40±0.17 3.72±0.09 2.73±0.10 0.975a 
p<0.0001b 
HDL-cholesterol (mmol/L)     
Triglycerides (mmol/L) 2.37±0.15 1.88±0.18 0.97±0.07 p<0.0001a 
0.0402b 
Fasting glucose (mmol/L) 6.33±0.27 5.44±0.16 4.83±0.07 0.0056a 
0.0004b 
Fasting insulin (ulU/ml) 15.98±1.07 16.34±1.26 8.81±1.08 0.8281a 
p<0.0001b 
HBA1c (%) 6.59±0.19 5.70±0.10 5.82±0.05 p<0.0001a 
0.2796b 
hsCRP (mg/L) 7.99±1.14 6.69±1.12 6.42±1.04 0.4205a 
0.8806b 
Medication     
Statins (%) 85 3 0 p<0.0001a 
Aspirin (%) 88 0 0  
Beta blockers (%) 79 0 0  
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Nitrates (%) 38 0 0  
ACE-Is (%) 73 2 0 p<0.0001a 
Folate supplements n (%) 7 (7) 4 (4) 0 0.5395b 
 
LDL = Low density lipoprotein, HDL = High density lipoprotein, BMI = Body mass index, HBA1c = 
Glycated haemoglobin, hsCRP = High sensitivity C-reactive protein, ACE-Is = Angiotensin-
converting-enzyme inhibitors 
a Comparison between CAD patients and Indian controls 
b Comparison between Indian and Black controls 
 
 
CAD patients’ characteristics according to MTHFR genotype are presented in Table 3.3. There were 
no significant differences observed between the wild type and variant genotypes. CAD patients 
harboring the variant genotypes had similar total cholesterol, LDL, HDL, BMI, etc. compared to those 
with the homozygous wildtype genotype. 
 
Table 3.3 Characteristics of CAD patients according to MTHFR genotype 
 
 MTHFR genotype p-value 
 Wild type (CC) Variant (CT+TT)  
Diabetes n (%) 48 (61%) 15 (56%) ns 
Total cholesterol (mmol/L) 5.43±0.21 5.10±0.32 ns 
LDL (mmol/L) 3.45±0.20 3.23±0.31 ns 
HDL (mmol/L) 0.93±0.03 0.90±0.06 ns 
Triglycerides (mmol/L) 2.45±0.18 2.13±0.26 ns 
BMI (kg/m2) 27.86±0.51 29.00±0.96 ns 
Fasting glucose (mmol/L) 6.27±0.32 6.52±0.52 ns 
Fasting insulin (ulU/ml) 14.99±1.18 18.87±2.37 ns 
HbA1c (%) 6.45±0.22 7.00±0.38 ns 







In the present study, we observed a significantly higher prevalence of the MTHFR 677 variant allele 
in CAD patients compared with Indian controls. However, no correlation between the SNP and 
clinical characteristics associated with CAD was found. 
 
Similar findings were observed in a North Indian population, where the MTHFR T allele was 
significantly associated with CAD (Tripathi, Tewari et al. 2012). However, another study in India 
found a very low prevalence of the MTHFR variant allele in CAD patients (Gupta, Kotwal et al. 
2012). The relationship between the MTHFR C677T SNP and CAD remains controversial, with 
reports in favour of and contradicting this association. Literature shows that MTHFR genotype 
frequencies vary amongst populations of different ethnic background (Motti, Gnasso et al. 1998; 
Ueland, Hustad et al. 2001; Gupta, Kotwal et al. 2012). Frequencies of the MTHFR homozygous 
variant genotype in control populations ranged from 1.4% in African Americans, to 5% in Dutch and 
Finnish, to 10% in Japanese and in Australians, to 11.5% in white populations in US (Girelli, Friso et 
al. 1998; Motti, Gnasso et al. 1998). 
 
Nienaber-Rousseau et al. recently investigated the frequency of the MTHFR C677T SNP and its 
effect on homocysteine levels in a cohort of Black South Africans. It was observed that 15.2%, 0.8%, 
and 84% of the study population harboured the MTHFR 677 CT, TT, and CC genotypes respectively 
(Nienaber-Rousseau, Ellis et al. 2013). Subjects with the MTHFR 677 TT genotype exhibited the 
highest homocysteine levels while those homozygous for the wild type allele had the lowest 
homocysteine levels. Low prevalence of the MTHFR TT genotype among Black South Africans was 
speculated to confer protection to this population against risk of homocysteine associated disease. Our 
study supports the findings of Nienaber-Rousseau et al. with regards to the low prevalence of the 
MTHFR TT genotype observed amongst Black South Africans.   
 
Nutritional status may be a reason for the differences observed in various studies, as folate deficiency 
may be a required condition for the detrimental consequence of the MTHFR C677T SNP on the 
enzyme (Farbstein and Levy 2010). Italians have among the highest ever reported frequency of the 
MTHFR TT genotype (considered to be a genetic marker of risk for vascular disease), but the overall 
prevalence of vascular complications is relatively low (Motti, Gnasso et al. 1998). This paradox could 
be explained by different dietary habits. Italians generally follow a Mediterranean diet, consisting of 
food high in folate content and therefore could counteract the effects of the MTHFR variant. 
 
In contrast, findings from a study done on the Turkish population suggest that the MTHFR C677T 
SNP may be a risk for premature myocardial infarction (Gulec, Aras et al. 2001). The Turkish are 
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known for having low levels of plasma folate (Tokgozoglu, Alikasifoglu et al. 1999). This supports 
the hypothesis that the MTHFR C677T SNP increases the risk of CAD and other vascular 
complications in individuals with low folate levels, while in well-nourished populations it may be 
tolerated without detrimental consequences. 
 
We found an association between the MTHFR 677 variant and CAD in South African Indians. The 
higher frequency of the MTHFR C677T SNP in SA Indians may increase their risk of CAD compared 
to Blacks. A larger follow up study may be required to assess the significance of this SNP. 
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Background: Sirtuin 1 (SIRT1), a class III histone deacetylase, has been identified as a candidate 
molecule affecting the epigenetic mechanisms of cardiovascular disease (CVD). Previous studies have 
shown that some SIRT 1 single nucleotide polymorphisms (SNPs) are associated with body mass 
index, diabetes, blood pressure, cholesterol metabolism, and coronary artery calcification. We 
investigated two A>G SIRT1 SNPs, rs1467568 and rs7895833, in young South African (SA) Indians 
with coronary artery disease (CAD) and compared them to Indian and Black controls.  
Methods: For rs1467568, a total of 287 subjects were recruited into this study (104 CAD patients, 99 
age-, sex-, and race-matched controls, and 84 age- and sex-matched Black controls). For rs7895833, a 
total of 281 subjects were recruited into this study (100 CAD patients, 99 age-, sex-, and race-matched 
controls, and 82 age- and sex-matched Black controls). All patients were male, of Indian ethnicity, 
confirmed on angiography, mean age 37.5; range 24-45 years. All subjects were genotyped using 
TaqMan SNP Genotyping Assays. 
Results: The variant allele for both SNPs was found at a higher frequency in the total Indian group 
compared to the total Black population (rs1467568: 41% vs. 18.5% respectively, p<0.0001, 
OR=3.190 95% CI 2.058 – 40943 and rs7895833: 41% vs. 22% respectively, p<0.0001, OR=2.466 
95% CI 1.620 – 3.755). Indian controls presented with a higher frequency for both SNPs compared to 
Black controls (rs1467568: 40% vs. 18.5% respectively, p<0.0001, OR=2.996 95% CI 1.850 – 4.853 
and rs7895833: 41% vs. 22% respectively, p<0.0001, OR=2.513 95% CI 1.578 – 4.004). No 
difference was seen in the distribution of both SNPs between CAD patients and either control group. 
We did not observe any association between the SNPs and clinical parameters in CAD patients and 
controls. 
Conclusion: Both SNP variant alleles occur more frequently in SA Indians than in SA Blacks. A 
larger study group and further analysis is required to assess whether these SIRT1 SNPs may serve as 
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Sirtuins are a class of NAD+-dependent proteins involved in a wide range of biological processes such 
as aging, transcription, apoptosis, and inflammation.1 Sirtuin 1 (SIRT1) is located in the nucleus and 
the cytoplasm, and plays an important role in epigenetic regulation by deacetylating a range of 
transcription factors to control downstream gene expression.2 The targets of SIRT1 include Forkhead 
box O (FOXO)1, FOXO3, peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
(PGC-1α), tumour suppressor p53, nuclear factor-kappa B (NF-κB), Notch, hypoxia-inducible factor 
(HIF)1α, liver X receptor (LXR), farnesoid X receptor (FXR), and sterol regulatory element-binding 
protein (SREBP)1c.3  
Recent studies have demonstrated a protective role of SIRT1 in atherosclerosis, the underlying 
process of coronary artery disease (CAD).4 SIRT1 performs an anti-inflammatory function by 
downregulating the expression of several pro-inflammatory cytokines by interfering with the NF-κB 
signalling pathway. By deacetylating NF-κB, SIRT1 suppresses the expression of lectin-like oxidised 
low-density lipoprotein receptor-1 (Lox-1), a scavenger receptor for oxidised low-density lipoproteins 
(oxLDL), therefore preventing foam cell formation.4 SIRT1 controls the activity of LXR, and 
important regulator of lipid homeostasis and inflammation.4 Activation of LXR results in expression 
of ATP-binding cassette (ABC) transporter ABCA1 that regulates the removal of cholesterol into high 
density lipoproteins (HDL), a process known as reverse cholesterol transport (RCT). Dysfunctional 
RCT could lead to accumulation of cholesterol, thus stimulating foam cell production and the 
progression of atherosclerosis.4, 5 Given the important role of SIRT1 in cardiovascular disease, 
research on genetic variation in the SIRT1 gene has become of interest. 
Genetic variations such as single nucleotide polymorphisms (SNPs) in the SIRT1 gene has been 
associated with inflammation, body mass index, type 2 diabetes, blood pressure, and dyslipidemia, all 
of which are well-established risk factors for CAD.2, 6-9 Coronary artery disease remains a leading 
cause of mortality worldwide, with an unusually high prevalence of early-onset disease among the 
Indian population. South African (SA) Indians have a much higher prevalence of CAD compared to 
SA Blacks.10 There are currently no studies on SIRT1 SNPs in SA Indians with CAD. We therefore 
investigated the SIRT1 A>G SNPs, rs1467568 and rs7895833, in young SA Indians with CAD and 










A total of 287 subjects were recruited into this study (104 CAD patients, 99 age-, sex-, and race-




A total of 281 subjects were recruited into this study (100 CAD patients, 99 age-, sex-, and race-
matched controls, and 82 age- and sex-matched Black controls) following institutional ethical 
approval (BE067/14). 
 
The inclusion criteria for CAD patients were: Indian ancestry and unrelated, adult males aged <45 
years, and stable CAD confirmed on angiography. The exclusion criteria for controls included an 
acute coronary syndrome/revascularisation procedure in the preceding 3 months, chronic renal or liver 
disease, malignancy and known inflammatory or infectious disease. 
 
Clinical markers 
Blood samples were obtained following an overnight fast. A full pathology report of clinical markers 
was assessed by routine laboratory testing at Global Clinical and Viral Laboratory (Durban, South 
Africa), a South African National Accreditation System (SANAS) certified laboratory. The following 
parameters were tested: Haematology (Roche Sysmex 1800XT), Chemistry (Beckman Coulter 
DXC600), Endocrinology and hsCRP (Siemens Centaur XP), Serology (BD Biosciences FACS 
Calibur), as per international standards to obtain levels of total cholesterol, HDL, LDL, triglycerides, 
fasting glucose, 2-h glucose, fasting insulin, glycosylated haemoglobin, sodium, potassium, 
bicarbonate, chloride, urea, creatinine, glomerular filtration rate, CD4 count, CD8 count, CD45 count 
and CD3 count. The physical measurements of weight, height, abdominal circumference, waist 





Genomic DNA was extracted from the whole blood sample of each patient and control, according to 
the method described by Sambrook et al.11 Cells were transferred to 600 μl lysis buffer (0.5 % sodium 
dodecyl sulphate (SDS), 150 mM NaCl, 10 mM ethylenediaminetetra-acetic acid (EDTA), 10 mM 
Tris–HCl (pH 8.0)). To this, RNase A (100 μg/ml; DNase-free) was added to the solution and 
incubated (37 °C, 1 h). Proteinase K (200 μg/ml) was then added and incubated (3 h, 50 °C). Protein 
contaminants were then precipitated by adding 5 mM 0.1 % potassium acetate before centrifugation 
(5,000×g; 15 min). Supernatants containing genomic DNA were transferred to fresh tubes and 
extracted with 100 % isopropanol on ice, and thereafter washed with 70 % ethanol. DNA samples 
were dissolved in 10 mM Tris and 0.1 mM EDTA (pH 7.4, 4 °C). DNA concentration was determined 




Following the manufacturer’s protocol, TaqMan® SNP Predesigned Genotyping Assay (Life 
Technologies, Cat #4351379) was used to genotype all subjects for both SNPs.  
The TaqMan Predesigned Genotyping Assay contains two primers for amplifying the sequence of 
interest and two TaqMan® minor-groove binding (MGB) probes for detecting alleles. The presence of 
two probe pairs in each reaction allows genotyping of the two possible variant alleles at the SNP site 
in a DNA target sequence. The genotyping assay determines the presence or absence of a SNP based 
on the change in fluorescence of the dyes associated with the probes. The TaqMan® MGB Probes 
consist of target-specific oligonucleotides with a reporter dye at the 5´ end of each probe: One VIC®-
labelled probe to detect Allele 1 sequence (A-allele in the case of rs1467568 and rs7895833) and one 
FAM™ labelled probe to detect Allele 2 sequence (G-allele in the case of rs1467568 and rs7895833). 
A fluorescence signal for both dyes indicates heterozygous for allele 1-allele 2 (AG). 
A final reaction mixture consisted of 40× TaqMan® Predesigned Genotyping Assay, 2X TaqMan® 
Genotyping Master Mix, nuclease-free water, and a 10ng genomic DNA template. The experiment 








The Hardy–Weinberg equilibrium was used to test for deviation of allele/genotype frequency. All 
other statistical analysis was performed with Graphpad prism software (version 5.0). Allele and 
genotype frequencies were calculated using the Fisher’s exact and Chi square tests, respectively. The 
comparison of biochemical measures between the wildtype and variant genotypes were done by a 
nonparametric t test. Results are expressed as mean ± standard error. A p value less than 0.05 was 





The genotype distribution complied with the Hardy-Weinberg equilibrium in CAD patients and Indian 
controls (Chi squared p=0.233 and p=0.941, respectively), but not in the Black control group (Chi 
squared p<0.05). 
No significant difference was observed in the distribution of the SIRT1 rs1467568 alleles between 
CAD patients and Indian controls (41% vs. 40% respectively, p=0.9196, OR = 1.040 95% CI 0.6998-
1.545). Indian controls presented with a higher frequency of the variant allele compared to the Black 
controls (40% vs. 18.5% respectively, p<0.0001, OR=2.996 95% CI 1.850 – 4.853). The variant allele 
was found at a higher frequency in the total Indian group compared to the total Black population (41% 
vs. 18.5% respectively, p<0.0001, OR=3.057 95% CI 1.974 – 4.733) (Table 4.1). 
 
SIRT1 rs7895833 
The genotype distribution complied with the Hardy-Weinberg equilibrium in CAD patients, Indian 
controls, and Black controls (Chi squared p=0.970 and p=1.000, and p=0.164 respectively). 
No significant difference was observed in the distribution of the SIRT1 rs7895833 alleles between 
CAD patients and Indian controls (40.5% vs. 41% respectively, p=0.9188, OR=0.9629 95% CI 
0.6457-1.436). Indian controls presented with a higher frequency of the variant allele compared to the 
Black controls (41% vs. 22% respectively, p<0.0001, OR=2.513 95% CI 1.578 – 4.004). The variant 
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allele was found at a higher frequency in the total Indian group compared to the total Black population 
(41% vs. 22% respectively, p<0.0001, OR=2.466 95% CI 1.620 – 3.755) (Table 4.1). 
 















Genotypes     
AA 40 (38.46%) 36 (36.36%) 76 (37%) 62 (73.81%) 
AG 42 (40.38%) 46 (46.46%) 88 (43%) 13 (15.48%) 
GG 22 (21.15%) 17 (17.17%) 39 (19%) 9 (10.71%) 
Alleles     
A 122 (59%) 118 (60%) 240 (59%) 137 (81.5%) 













Genotypes     
AA 36 (36%) 34 (34.34%) 70 (35%) 47 (57.32%) 
AG 47 (47%) 48 (48.48%) 95 (48%) 34 (41.46%) 
GG 17 (17%) 17 (17.17%) 34 (17%) 1 (1.22%) 
Alleles     
A 119 (59.5%) 116 (59%) 235 (59%) 128 (78%) 
G 81 (40.5%) 82 (41%) 163 (41%) 36 (22%) 
 
 
Characteristics of study participants were reported previously.[12] As expected, CAD patients 
presented with more conventional risk factors (higher body mass index [BMI], total and LDL 
cholesterol, triglycerides, and a higher prevalence of type 2 diabetes mellitus) than the control groups. 
No association between the SIRT1 SNPs and biochemical measures were found in CAD patients 
(Table 4.2), Indian controls (Table 4.3) and Black controls (Table 4.4). 
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Table 4.2 Characteristics of CAD patients according to the SIRT1 rs1467568 and SIRT1 
rs7895833 genotypes 
 
 SIRT1 rs1467568 genotype p-value SIRT1 rs7895833 genotype p-
value 









BMI (kg/m2) 27.52±0.81 28.57±0.55 ns 28.02±0.80 28.33±0.59 ns 
Total cholesterol 
(mmol/L) 
5.73±0.32 5.17±0.20 ns 5.32±0.24 5.46±0.25 ns 
LDL (mmol/L) 3.70±0.29 3.27±0.21 ns 3.41±0.23 3.47±0.24 ns 
HDL (mmol/L) 0.98±0.04 0.89±0.03 ns 0.91±0.04 0.93±0.04 ns 
Triglycerides 
(mmol/L) 
2.41±0.28 2.37±0.18 ns 2.34±0.24 2.38±0.20 ns 
Fasting glucose 
(mmol/L) 
6.48±0.50 6.27±0.33 ns 6.18±0.47 6.32±0.34 ns 
Fasting insulin 
(ulU/ml) 
16.97±2.21 15.54±1.12 ns 14.17±1.19 16.95±1.61 ns 
HBA1c (%) 6.63±0.33 6.61±0.24 ns 6.57±0.34 6.60±0.24 ns 
hsCRP (mg/L) 9.83±2.58 6.97±0.98 ns 8.93±2.42 7.78±1.31 ns 












Table 4.3 Characteristics of Indian controls according to the SIRT1 rs1467568 and SIRT1 
rs7895833 genotype 
 
 SIRT1 rs1467568 genotype p-value SIRT1 rs7895833 genotype p-
value 









BMI (kg/m2) 25.88±0.93 26.65±0.69 ns 25.14±1.01 26.88±0.66 ns 
Total cholesterol 
(mmol/L) 
5.32±0.16 5.54±0.13 ns 5.56±0.19 5.41±0.12 ns 
LDL (mmol/L) 3.47±0.13 3.86±0.12 ns 3.88±0.17 3.63±0.11 ns 
HDL (mmol/L) 1.04± 0.07 0.91±0.03 ns 0.97±0.07 0.95±0.03 ns 
Triglycerides 
(mmol/L) 
1.79±0.22 1.92±0.27 ns 1.63±0.17 2.00±0.27 ns 
Fasting glucose 
(mmol/L) 
5.59±0.34 5.38±0.16 ns 5.27±0.20 5.56±0.22 ns 
Fasting insulin 
(ulU/ml) 
15.91±1.96 16.72±1.66 ns 13.36±1.46 18.03±1.75 ns 
HBA1c (%) 5.78±0.21 5.65±0.11 ns 5.85±0.16 5.63±0.13 ns 
hsCRP (mg/L) 4.58±0.60 7.95±1.71 ns 6.52±1.41 6.87±1.57 ns 












Table 4.4 Characteristics of Black controls according to the SIRT1 rs1467568 and SIRT1 
rs7895833 genotype 
 
 SIRT1 rs1467568 genotype p-
value 
SIRT1 rs7895833 genotype p-
value 









BMI (kg/m2) 25.53±0.54 27.13±1.20 ns 25.58±0.63 26.57±0.87 ns 
Total cholesterol 
(mmol/L) 
4.12±0.12 4.47±0.23 ns 4.30±0.13 4.14±0.18 ns 
LDL (mmol/L) 2.62±0.10 3.02±0.22 ns 2.78±0.12 2.71±0.16 ns 
HDL (mmol/L) 1.05± 0.045 1.03±0.088 ns 1.08±0.05 0.99±0.06 ns 
Triglycerides 
(mmol/L) 
0.99±0.072 0.93±0.15 ns 0.98±0.08 0.96±0.11 ns 
Fasting glucose 
(mmol/L) 
4.80± 0.084 4.90±0.11 ns 4.87±0.11 4.77±0.08 ns 
Fasting insulin 
(ulU/ml) 
7.69±0.67 12.11±3.74 ns 9.21±1.73 8.59±1.10 ns 
HBA1c (%) 5.83±0.062 5.79±0.082 ns 5.87±0.07 5.76±0.077 ns 
hsCRP (mg/L) 6.64±1.86 5.82±1.23 ns 7.81±2.42 4.83±0.84 ns 
 
BMI = body mass index, LDL = Low density lipoprotein, HDL = High density lipoprotein, HBA1c = 




Indian populations throughout the world show early-onset CAD, one to two decades earlier than other 
ethnic groups.13 South African Indians have the highest mortality rates due to CAD, while Black 
South Africans have a very low prevalence of the disease.10   
Increasing evidence has shown that SIRT1 is involved in CAD by regulating a number of key 
metabolic and physiological processes. Sirtuin 1 serves as an anti-atherosclerotic factor by mediating 
endothelial nitric oxide synthase (eNOS) and improving endothelial dysfunction, regulating 




Several SNPs have been identified in SIRT1, a candidate molecule involved in the epigenetic 
regulation of CAD. To date, there are only a few human genetic association studies regarding SIRT1 
SNPs and CAD. The present study was the first investigation of SIRT1 rs1467568 and rs7895833 in 
SA Indian CAD patients. We observed that the variant alleles of both SIRT1 SNPs occurred more 
frequently in SA Indians compared to SA Blacks. We did not observe any difference in allele 
frequencies between CAD patients and control groups. 
Previous studies showed that some of the SIRT1 SNPs are associated with BMI and obesity, glucose 
tolerance and diabetes, blood pressure, cholesterol metabolism and coronary artery calcification, all of 
which contribute to CAD phenotype.15-19 We examined the possible association between rs1467568 
and rs7895833 in SIRT1 and BMI, total cholesterol, LDL, HDL, triglycerides, fasting glucose, fasting 
insulin, HbA1c, hsCRP, or IL-6 in CAD patients and control groups, but did not observe any 
association. 
The Rotterdam study investigated SIRT1 variation (assessed by three tagging SIRT1 SNPs: 
rs7895833, rs1467568, and rs497849) in relation to BMI and risk of obesity in 4573 participants, 
including 413 individuals with prevalent and 378 with incident type 2 diabetes mellitus (T2DM).20 In 
subjects with prevalent T2DM, homozygous carriers the SIRT1 haplotype 1 had 1.9 times (95% CI 
1.1-3.2) increased risk of CVD mortality compared to non-carriers. An intended replication study 
(Erasmus Rucphen Family study) was carried out involving 2347 participants. Both studies observed 
that the minor alleles of rs7895833 (G allele) and rs1467568 (A allele) were associated with lower 
BMI and a 13-18% decreased risk of obesity in two independent Dutch populations. 17 In another 
study, the A allele of rs7895833 was associated with increased risk of obesity and hypertension in 
Japanese men.15 
Recent studies investigated the association between SIRT1 SNPs (rs7895833, rs7069102, 
rs144124002 and rs2273773) and CAD in a Turkish population. While rs7069102, rs2273773 and 
rs144124002 were significantly associated with increased risk for CAD, they found no association 
between rs7895833 and CAD.21, 22  
Shimoyama et al. reported that SIRT1 rs7069102 and rs2273773 are associated with abnormal 
cholesterol metabolism and coronary artery calcification, respectively, in Japanese haemodialysis 
(HD) patients. The study also found that the A allele frequency of SIRT1 rs7895833 and G allele 
frequency of rs7069102 were significantly lower in HD patients compared to controls, suggesting an 




The allele frequency of rs7895833 and rs1467568 show ethnic variation, and is a possible reason for 
differing disease patterns among populations. The frequency of the rs7895833 A allele was relatively 
low (0.29) in Japanese compared to Dutch, Turkish and Caucasians who had similar allele frequencies 
(0.80, 0.85, and 0.80 respectively).15, 17, 24 The A allele of rs1467568 (reported as the protective allele) 
showed marked difference in frequency between the European (0.25) and Japanese (0.84).24 
 
Conclusion 
Both SNP variant alleles occur more frequently in SA Indians than in SA Blacks, but no difference 
was found between CAD patients and controls. The present study is limited by sample size and a 
larger study may be required to fully assess the functional significance of these polymorphisms. 
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Background: MicroRNA (miR)-499 is an inflammatory-associated miR implicated in chronic 
diseases such as coronary artery disease (CAD) which affects South Africans of Indian ethnicity. 
Objectives: To report the frequency of the miR-499 A>G single nucleotide polymorphism (SNP) 
(rs3746444) in young South African (SA) Indians and Blacks, and investigate its association with 
CAD. 
Methods: A total of 289 subjects were recruited into this case-control study which included 105 CAD 
patients (diagnosed on angiography, mean age 37.5; range 24-45 years), 100 age-, sex-, and race-
matched controls, and 84 age- and sex-matched Black controls. Polymerase chain reaction-Restriction 
fragment length polymorphism (PCR-RFLP) was used to genotype all subjects. Interleukin (IL)-6 was 
measured by ELISA, and all other biochemical markers were provided by pathology reports. 
Results: The miR-499 variant allele was found at a higher frequency in the total Indian group (34%) 
compared to the total Black population (22%) (p=0.0070, OR=1.796 95% CI 1.182 – 2.730). Indian 
cases presented with higher frequency of the variant allele compared to Indian controls (38% vs. 29%, 
p = 0.059, respectively). Higher levels of hsCRP and IL-6 were observed in CAD patients with the 
variant genotypes compared to those with the wild type genotypes (8.92±1.91 vs. 6.73±0.87 mg/L; 
p=0.299, 3.02±0.77 vs. 2.18±0.57 pg/mL; p=0.381 respectively). 
Conclusion: The higher frequency of rs3746444 variant in SA Indians may be a contributing factor to 
the higher risk profile for the development of premature CAD in Indians. The A-to-G change in miR-
499 seed sequence may interfere with its binding to and interaction with targets, thereby regulating 
inflammation in CAD patients. 
 
 
Key words: microRNA-499, Single nucleotide polymorphism, rs3746444, early-onset coronary 








Coronary artery disease (CAD) is a multifactorial chronic inflammatory disease depending on the 
complex interaction amongst environmental and lifestyle associated risk factors, and several 
predisposing genes.[1] On a genetic level, single nucleotide polymorphisms (SNPs) in key genes may 
play a role in an individual’s susceptibility to the manifestation of the disease. The role of SNPs in 
protein coding genes has been well investigated, but remains poorly understood in microRNAs 
(miRs).  
MicoRNAs are a class of small noncoding RNA molecules that negatively regulate gene expression of 
target genes by inhibiting messenger RNA (mRNA) translation or promoting mRNA degradation.[2, 3] 
A single miR is able to regulate multiple target genes whereas one target gene may be regulated by 
various miRs.[4] MicroRNAs regulate most biological processes; therefore aberrant miR expression is 
likely to be implicated in several pathological conditions.[5, 6] Genetic variation such as SNPs in miRs 
may affect their processing, expression and interaction with target genes.[4] Altered miR expression 
has been well investigated in various diseases [7, 8] but miRs in cardiovascular disease is still an 
emerging field of research with very few studies focusing on coronary artery disease.[9] 
We recently showed that a common SNP in miR-146a (rs2910164) influences the expression of 
mature miR-146a in CAD patients. MicroRNA-146a primarily targets interleukin-1 receptor-
associated kinase 1 (IRAK-1) and tumour necrosis factor receptor associated factor 6 (TRAF-6), 
which results in inhibition of nuclear factor kappa-B (NF-κB) via the toll-like receptor (TLR) 
pathway. We found that CAD patients with the variant (CC) genotype were associated with 
significantly higher levels of miR-146a. The targets of miR-146a, IRAK-1 and TRAF-6, were 
significantly lower in these patients (CC genotype). The lowest levels of NF-κB and C-reactive 
protein (CRP) were found in patients with the homozygous C allele compared to the heterozygous GC 
and wildtype variants. The results of our study suggested a role for miR-146a as a target for lowering 
inflammation in CAD patients.[10] 
Inflammatory cytokines play an important role in the pathogenesis and development of CAD. 
Increased levels of proinflammatory cytokines have been associated with worse prognosis of CAD. 
Several cytokines, including interleukin (IL)-17 receptor β (IL-17Rβ), IL-23a, IL-2β, IL-6, IL-2, IL-
18R, and IL-21 are well known targets of miR-499.[5, 11] MicroRNA-499 has been implicated in 
inflammatory diseases such as rheumatoid arthritis (RA), and pulmonary tuberculosis (PTB).[5, 12] 
A common miR-499 A/G SNP (rs3746444) located within the crucial seed sequence of miR-499 
results in a change from an A:U pair to a G:U mismatch in the stem structure of miR-499.[13, 14] The 
variant G allele has a less stable secondary structure than the wildtype allele and directly affects the 
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binding to target mRNAs, therefore altering protein expression and potentially contributing to disease 
susceptibility. 
Coronary artery disease remains one of the leading causes of death worldwide, with an unusually high 
prevalence of early-onset CAD in Indians. South African Indians have a much higher prevalence of 
CAD compared to Black South Africans.[15] To date, there is no literature available on rs3746444 in 
South African Indians. This study aimed to assess the frequency and role of this SNP in young Indian 
CAD patients compared to Indian and Black controls. 
 
METHODS 
Patient Recruitment and Sample Collection 
Following institutional ethical approval (BE067/14), a total of 289 subjects were recruited into this 
study which included 105 CAD patients (diagnosed by angiography, mean age 37.5; range 24-45 
years), 100 age-, sex-, and race-matched controls, and 84 age- and sex-matched Black controls. A full 
pathology report of clinical markers was assessed by routine laboratory testing at Global Clinical and 
Viral Laboratory (Durban, South Africa) - a fully accredited South African National Laboratory. The 
following parameters were tested: Haematology (Roche Sysmex 1800XT), Chemistry (Beckman 
Coulter DXC600), Endocrinology and high sensitivity C-reactive protein (hsCRP) (Siemens Centaur 
XP), Serology (BD Biosciences FACS Calibur), as per international standards to obtain levels of total 
cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides, fasting 
glucose, 2-h glucose, fasting insulin, glycosylated haemoglobin (HbA1c), sodium, potassium, 
bicarbonate, chloride, urea, creatinine, and glomerular filtration rate. The physical measurements of 
weight, height, abdominal circumference, waist circumference and patient history were conducted by 
the cardiologist (Dr. S. Khan). The inclusion criteria for CAD patients were: Indian ancestry and 
unrelated, adults aged <45 years, and stable CAD confirmed at angiography. The exclusion criteria for 
controls included an acute coronary syndrome/revascularisation procedure in the preceding 3 months, 
chronic renal or liver disease, malignancy and known inflammatory or infectious disease. 
 
DNA Extraction 
Genomic DNA was extracted from the whole blood sample of each subject, according to the method 
described by Sambrook et al.[16] Cells were transferred to 600 μl lysis buffer (0.5% sodium dodecyl 
sulphate (SDS), 150 mM NaCl, 10 mM ethylenediaminetetra-acetic acid (EDTA), 10 mM Tris–HCl 
(pH 8.0)). To this, RNase A (100 μg/ml; DNase-free) was added to the solution and incubated (37°C, 
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1 h). Proteinase K (200 μg/ml) was then added and incubated (3 h, 50°C). Protein contaminants were 
then precipitated by adding 5 mM 0.1% potassium acetate before centrifugation (5,000 ×g; 15 min). 
Supernatants containing genomic DNA were transferred to fresh tubes and extracted with 100% 
isopropanol on ice, and thereafter washed with 70% ethanol. DNA samples were dissolved in 10 mM 
Tris and 0.1 mM EDTA (pH 7.4, 4°C). DNA concentration was determined using the Nanodrop2000 
spectrophotometer, and all samples were standardised to a concentration of 10 ng/μl. 
 
Genotyping 
An optimised polymerase chain reaction (PCR) was used to obtain the highest specificity and yield of 
the PCR product. This was achieved by amplification of the genomic DNA using 40 ρmol of each 
primer (Forward Primer: 5'- ATTGGATGCCGCAGTGGT-3'; Reverse Primer: 5'-
TGTTTAACTCCTCTCCACGTGATC-3').[17] A no-template sample was run with the positive 
samples as a quality control measure against PCR contamination. The 25 μl reaction consisted of 200 
μM of each dNTP, 2.5 mM MgCl2, 1× Green GoTaq Flexi buffer, 0.5U Go-Taq DNA polymerase 
(Promega) and 30 ng genomic DNA template. PCR was performed under the following cycling 
conditions: 94°C for 5 min (initial denaturation), followed by 34 cycles of 94°C for 30 s, 59 °C for 30 
s (annealing), 72°C for 30 s (extension), and 72°C for 7 min (final extension). PCR products were 
electrophoresed on agarose gel (1.8%, 0.5 mg/ml ethidium bromide) and visualised using the Uvitech 
image documentation system (Uvitech Alliance 2.7). PCR–RFLP was used to determine rs3746444 
genotypes. 15 μl of each PCR product was subjected to restriction by 1 μl (10 u/μl) Bcl I and 2 μl 10× 
Buffer G (Fermentas). Overnight restriction occurred at 55°C, and thereafter restriction products were 
electrophoresed on agarose gel (3%, 0.5 mg/ml ethidium bromide) and visualised as was the PCR 
product. Two fragments of 239 bp and 24 bp were observed for the wild-type A allele, while the 
variant G allele yielded a single band of 263 bp. Restriction products were run alongside a DNA 
ladder for accurate reading of fragment sizes, thus enabling correct analysis of genotypes. 
 
IL-6 enzyme-linked immunosorbent assay 
A human IL-6 ELISA Kit II (BD OptEIA™) was used to measure the IL-6 levels of patients and 
controls (in duplicate). As per the user manual, enzyme-linked immunosorbent assay (ELISA) diluent 
(12ml of buffered protein base, 0.09% sodium azide) was added to a 96-well microtiter plate coated 
with antihuman IL-6 monoclonal antibody, and standards and samples were added into appropriate 
wells. Following incubation for 2 hr at room temperature, wells were rinsed with wash buffer (1× 
detergent solution with ProClin™-150). 
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Working detector (containing streptavidin–horseradish peroxide and biotinylated anti-human IL-6 
monoclonal antibody) was added into each well and incubated for 1 hr at room temperature in the 
dark). Wells were washed as previously, seven times, followed by the addition of TMB One-Step 
Substrate Reagent (3,3’,5,5’-tetramethylbenzidine) and incubated for 30 min at room temperature in 
the dark. Following incubation, stop solution (1M phosphoric acid) was added, and absorbance 
measured at 450 nm (reference, 570 nm) with a microplate reader (Bio-Tek µQuant). 
 
Statistical Analysis 
The Hardy–Weinberg equilibrium was used to test for deviation of allele/genotype frequency. All 
other statistical analysis was performed with Graphpad prism software (version 5.0). Allele and 
genotype frequencies were calculated using the Fisher’s exact and Chi square tests, respectively. 
Characteristics of CAD patients according to genotype was analysed by a non-parametric T-test. 





The miR-499 rs3746444 genotype distribution complied with the Hardy-Weinberg equilibrium in 
CAD patients, Indian controls, and Black controls (Chi-squared p=0.143479, p=0.742181, and 
p=0.419581 respectively). The variant (G) allele was found at a higher frequency in the total Indian 
group (34%) compared to the total Black population (22%) (p=0.0070, OR=1.796 95% CI 1.182 – 
2.730; Table 1). Indian cases presented with higher frequency of the variant allele compared to Indian 













Table 5.1 miR-499 rs3746444 genotype and allele frequency in CAD patients and controls 
 









AA 45 (43%) 52 (52%) 97 (47%) 49 (58.3%) 
AG 40 (38%) 38 (38%) 78 (38%) 33 (39.3%) 
GG 20 (19%) 10 (10%) 30 (15%) 2 (2.4%) 
Allele     
A 130 (62%) 142 (71%) 272 (66%) 131 (78%) 
G 80 (38%) 58 (29%) 138 (34%) 37 (22%) 
 
Characteristics of study participants were reported previously.[18] CAD patients’ characteristics 
according to rs3746444 genotypes are presented in Table 5.2. There were no significant differences 
observed between the wild type and variant genotypes. 
 
Table 5.2 Characteristics of CAD patients according to the miR-499 rs3746444 genotype 
 
 miR-499 rs3746444 genotype p-value 
 Wild type (AA) Variant (AG+GG)  
Total cholesterol (mmol/l) 5.36±0.25 5.34±0.25 ns 
LDL (mmol/l) 3.36±0.26 3.44±0.22 ns 
HDL (mmol/l) 0.92±0.04 0.93±0.03 ns 
Triglycerides (mmol/l) 2.64±0.28 2.18±0.16 ns 
BMI (kg/m2) 28.17±0.81 28.21±0.51 ns 
Fasting glucose (mmol/l) 6.82±0.52 5.99±0.27 ns 
Fasting insulin (ulU/ml) 16.24±1.71 15.79±1.41 ns 
HBA1c (%) 7.02±0.35 6.29±0.20 ns 
hsCRP (mg/l) 6.73±0.87 8.92±1.91 ns 
IL-6 (pg/ml) 2.18±0.57 3.02±0.77 ns 
 
LDL = Low density lipoprotein, BMI = Body mass index, HbA1c = Glycated haemoglobin, hsCRP = 
High sensitivity C-reactive protein, ns = non-significant 
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Elevated hsCRP and IL-6 levels were observed in CAD patients harboring the variant genotypes 
compared to those with the wild type genotypes (8.92±1.91 vs. 6.73±0.87 mg/l, 3.02±0.77 vs. 
2.18±0.57 pg/ml respectively) (Table 5.2, Figure 5.1). 
 
 




Single nucleotide polymorphisms in miR genes may alter a wide spectrum of biological processes by 
affecting the expression and/or target interaction of miRs,[12]. A growing number of studies have 
revealed that rs3746444 affects the pathogenesis of several human diseases, including breast 
cancer,[19], hepatocellular carcinoma,[20], RA,[5], CAD,[21], chronic obstructive pulmonary disease,[4] 
and TB,[12].  
 
The present study was the first investigation of the frequency of rs3746444 in young Indian CAD 
patients compared to Indian and Black controls. We found that the variant allele occurred at a higher 
frequency in the total Indian group compared to the total Black population. Indian cases presented 
with higher frequency of the variant allele compared to Indian controls. The highest mortality rates for 
CAD in South Africa occurs in  Indians, followed by mixed race, white and black,[15]. The higher 
frequency of the variant allele in our Indian study group may be a contributing factor to the higher 




Yang et al observed that rs3746444 could affect the inflammatory response in RA patients,[5]. C-
reactive protein, erythrocyte sedimentation rate (ESR), IL-6, and TNF-α were used to indicate the 
degree of chronic inflammation in vivo in RA patients. The authors found that carriers of the 
heterozygous genotype had significantly higher levels of CRP and ESR compared to the homozygous 
wildtype and variant genotypes, indicating an important role for rs3746444 in the progress and 
inflammatory reaction of RA.  
We observed elevated levels of hsCRP and IL-6 in CAD patients harboring the variant compared to 
those with the wild type genotypes, but these were not significant. MiR-499 is known to target several 
inflammatory cytokines, including IL-6, which directly regulates the production of CRP,[11]. The 
change from A-to-G in miR-499 rs3746444 may interfere with its binding to and interaction with 
targets such as IL-6. Thus miR-499 can affect the synthesis of CRP and regulate inflammation in 
CAD patients. Li et al observed no link between rs3746444 and PTB risk in a Chinese Han group, but 
found that Tibetans carrying the variant allele exhibited increased risk of PTB,[12].  
Previous studies revealed that the GG and AG genotypes of rs3746444 conferred increased risk for 
CAD,[21]  and ischemic stroke,[22],respectively. To date, there have been only two published studies on 
the miR-499 rs3746444 with regards to CAD,[17, 21].  Recently, Zhi et al found that the GG genotype 
was associated with a 3.23-fold increased risk of CAD,[21]. In contrast, Xiong et al found no 
association between rs3746444 and CAD in a Chinese Han population,[17]. 
 
Our findings suggest that miR-499 may be a target for regulating inflammation in CAD patients. A 





The precise mechanisms regulating miR expression and target interaction remain unknown, but SNPs 
are known to play an important role. Small variation in miRs may affect several targets and result in 
diverse functional consequences, therefore SNPs in miRs may represent ideal candidate biomarkers 
for diseases prognosis and serve as a useful tool in therapeutic advances. 
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 South African Indians have a higher prevalence of early-onset CAD compared to Black South 
Africans. 
 Single nucleotide polymorphisms in microRNA genes, such as miR-499 rs3746444 may 
affect the expression and/or target interaction. 
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Modulation of nuclear factor KappaB (NF-κB) activation may play a role in regulating inflammatory 
conditions associated with coronary artery disease (CAD). MicroRNA-146a (miR-146a) primarily 
targets interleukin-1 receptor-associated kinase 1 (IRAK-1) and tumor necrosis factor (TNF) receptor 
associated factor 6 (TRAF-6), which results in inhibition of NF-κB via the TLR pathway. This study 
investigated the influence of the miR-146a GC rs2910164 on miR-146a expression in young South 
African Indians with CAD. CAD patients and controls were genotyped by PCR-RFLP and miRNA-
146a levels were measured by qPCR. IRAK-1, TRAF-6, and NF-κB expression was determined by 
western blot. No differences in genotypic frequency was found (GG: 45% vs. 47%, GC: 46% vs. 41%, 
CC: 9% vs. 12%) in controls and patients respectively (odds ratio (OR) = 1.025; 95% confidence 
interval (CI) 0.6782 – 1.550; p=0.9164).  Significantly higher levels of miR-146a was associated with 
CAD patients with the CC genotype (6.25-fold increase relative to controls and patients with the 
wildtype variant, p<0.0001). Significantly lower levels of IRAK-1 (0.38±0.02; p=0.0072) and TRAF-
6 (0.44±0.02; p=0.0146) was found in CAD patients with the CC genotype. The lowest levels of NF-
κB and C-reactive protein (CRP) were found in patients with the homozygous C allele compared to 
the heterozygous GC and wildtype variants. We propose a role for miR-146a in TLR signalling 
through a negative feedback mechanism involving the attenuation of NF-κB by down-regulation of 
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Micro-RNAs (miRs) are a class of small non-coding RNA that negatively regulate the expression of 
cognate target genes [1, 2]. MiRs attach to the 3’-untranslated region (3’-UTR) of their target 
messenger RNAs (mRNA) through their highly conserved seed sequence (2-7 nucleotides) [3, 4]. A 
single miR can potentially target hundreds of mRNA transcripts and can thus modulate transcriptional 
programs that affect entire cellular networks [5, 6]. Genetic alterations in miR sequences affect 
precursor processivity and thus maturation and expression of miRs. In addition, changes in the seed 
sequence alter binding kinetics between the mature miR and 3’-UTR target. It is conceivable that 
since miRs regulate magnitude of targets, small changes in genetic sequence will have large 
implications for transcriptional regulation and ultimately for the development of disease [7]. Single 
nucleotide polymorphisms (SNPs) have been well investigated in exons [8, 9], but little is known 
about their effect in miR and role in disease conditions. The miR-146a rs2910164 has been widely 
investigated in rheumatoid arthritis, tuberculosis and several cancers [1, 7, 10].  
Single nucleotide polymorphisms are the most common type of genetic variation in the human 
genome and have been well investigated in protein coding genes which affect the functioning of 
proteins and consequently render susceptibility to disease [8, 9]. There are limited studies focusing on 
the relationship between miR-146a expression and cardiovascular diseases [2, 11-13]. miR-146a is 
involved in regulating the innate immune, and inflammatory response pathways [14]. A common G/C 
SNP (rs2910164) located within the crucial seed sequence of miR-146a [15] causes a change from a 
G:U pair to a mismatched C:U in the stem region and was shown to affect the expression of mature 
miR-146a [1, 9]. Whether genetic variants of miR-146a confer differences in expression of miR-146a 
in CAD is unclear [1, 16, 17]. If such differences do occur, whether they are enough to produce 
significantly different regulatory effects on major mRNA targets remains unknown. 
miR-146a primarily targets IRAK-1 and TRAF-6, which are involved in TLR and IL-1 receptor (IL-
1R) signalling [18]. Upon stimulation of the TLR, the adaptor proteins myeloid differentiation 
primary-response gene 88 (MyD88) and TLR domain-containing adaptor-inducing interferon-β 
(TRIF) are recruited from the cell cytoplasm to the receptor, resulting in the activation of two 
independent branches of TLR signalling [19]. In the MyD88-dependent branch, MyD88 recruits 
IRAK-1, which in turn phosphorylates and activates TRAF-6. This chain of events leads to the 
phosphorylation and degradation of inhibitory kappa B (IκB), allowing NF-κB to enter the cell 
nucleus and activate the transcription of inflammatory genes [7, 19]. The effect of dysregulated miR-
146a expression on its target molecules IRAK-1 and TRAF-6 and their downstream functions in the 
TLR signalling pathway remain unclear. It is likely that alterations in miR-146a expression caused by 
genetic variation in miR-146a such as SNPs may affect TLR signalling. 
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CAD has been the leading cause of fatality worldwide since 1990 and this trend is expected to 
continue in the future [20, 21]. At present, developing countries such as South Africa and India 
contribute a large share to the global burden of CAD and are expected to account for 85% by 2020 
[20, 22]. Most South African Indians are descendants of indentured labourers who were brought from 
India between 1860 and 1911 [23]. Indians in India and South Africa show early onset of CAD, one to 
two decades earlier than other ethnic groups [24], indicating a genetic link. The highest death rates for 
CAD in South Africa occurs in Indians [25].  
The present study aimed to investigate the influence of miR-146a rs2910164 on miR-146a expression 
in young South African Indian CAD patients. This is the first investigation of the miR-146a SNP in 




2.1 Patient recruitment and Sample collection 
A total of 106 young Indian male CAD patients and 100 age- race- and sex-matched controls were 
enrolled following institutional ethical approval (BE154/010). A full pathology report of clinical 
markers was assessed by routine laboratory testing at the South African National Accredited System 
Global Clinical and Viral Laboratory (Amanzimtoti, South Africa). The following parameters were 
tested: Haematology (Roche Sysmex 1800XT), Chemistry (Beckman Coulter DXC600), 
Endocrinology and hsCRP (Siemens Centaur XP), Serology (BD Biosciences FACS Calibur) as per 
international standards to obtain levels of total cholesterol, HDL, LDL, triglycerides, fasting glucose, 
2h glucose, fasting insulin, glycosylated haemoglobin, sodium, potassium, bicarbonate, chloride, urea, 
creatinine, glomerular filtration rate, cell death (CD) 4 count, CD8 count, CD45 count and CD3 count. 
The physical measurements of weight, height, abdominal circumference, waist circumference and 
patient history were conducted by the clinician. The inclusion criteria for CAD patients were: Indian 
ancestry and unrelated, adults aged <45 years, and stable CAD confirmed at angiography. The 
exclusion criteria for controls included an acute coronary syndrome/ revascularisation procedure in 







2.2 DNA extraction 
Genomic DNA was extracted from the whole blood sample of each patient and control according to 
the method described by Sambrook et al. 2001 [26]. Cells were transferred to 600μl lysis buffer (0.5% 
sodium dodecyl sulphate (SDS), 150mM NaCl, 10mM ethylenediaminetetra-acetic acid (EDTA), 
10mM Tris-HCl (pH 8.0)). To this, RNase A (100 μg/ml; DNase-free) was added to the solution and 
incubated (37°C, 1 h). Proteinase K (200 μg/ml) was then added and incubated (3 h, 50°C). Protein 
contaminants were then precipitated by adding 5mM 0.1% potassium acetate before centrifugation 
(5000 xg; 15 min). Supernatants containing genomic DNA were transferred to fresh tubes and 
extracted with 100% isopropanol on ice and thereafter washed with 70% ethanol. DNA samples were 
dissolved in 10mM Tris and 0.1mM EDTA (pH 7.4, 4°C). DNA concentration was determined using 




An optimised polymerase chain reaction (PCR) was used to obtain the highest specificity and yield of 
the 147bp PCR product. This was achieved by amplification of the genomic DNA using 40 ρmol of 
each primer (Forward Primer: 5’-CATGGGTTGTGTCAGTGTCAGAGCT-3’ ; Reverse Primer: 5’-
TGCCTTCTGTCTCCAGTCTTCCAA -3’) [16]. A no-template sample was run with the positive 
samples as a quality control measure against PCR contamination. 
The 30µl reaction consisted of 200µM of each dNTP, 2.5mM MgCl2, 1× Green GoTaq Flexi buffer, 
0.2U GoTaq DNA polymerase (Promega) and 30ng genomic DNA template. PCR was performed 
under the following cycling conditions: 94°C for 10 minutes (initial denaturation), followed by 30 
cycles of 94°C for 30 seconds, 65°C for 30 seconds (annealing),  and 72°C for 7 minutes (final 
extension). PCR products were electrophoresed on agarose gel (1.8%, 0.5 mg/ml ethidium bromide) 
and visualised using the Uvitech image documentation system (Uvitech Alliance 2.7). 
PCR-RFLP was used to determine the miR-146a rs2910164 genotypes. 15µl of each PCR product 
was subjected to restriction by 1.5 µl (10u/µl) Sac I and 2µl 10× Buffer-Sac I (Fermentas). Overnight 
restriction occurred at 37°C and thereafter restriction products were electrophoresed on agarose gel 
(3%, 0.5 mg/ml ethidium bromide) and visualised as was the PCR product. Presence of the wild-type 
G-allele resulted in no cleavage of the PCR product. The variant C-allele yielded two fragments of 
122 and 25bp. The homozygous genotype yielded three bands of 147, 122, and 25bp. Restriction 
products were run alongside a DNA ladder for accurate reading of fragment sizes, thus enabling 
correct analysis of genotypes. 
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2.4 RNA extraction 
Total RNA was isolated from peripheral blood mononuclear cells (PBMC) from each miR-146a 
rs2910164 genotype in CAD patients and controls. RNA was isolated with Trizol reagent following 
an in-house protocol. Briefly, Trizol (300µl) was added to PBMCs and frozen for 1 hour at -80°C. 
Thereafter, chloroform (100µl) was added and centrifuged at (12000×g, 15 minutes, 4°C). 
Isopropanol (250µl) was added to the aqueous phase and once again subjected to freezing (1 hour, -
80°C). This was followed by centrifuging (12000×g, 20 minutes, 4°C), and then washing with 500µl 
cold ethanol (75%). Finally, samples were centrifuged at 7400×g for 15 minutes (4°C). Ethanol was 
removed and RNA pellets were resuspended in 15µl nuclease-free water. 
RNA was quantified using the Nanodrop2000 spectrophotometer. The ratio of absorbance at 260nm 
and 280nm was used to assess the purity of RNA, and samples were run on 2% agarose gel to check 
the integrity of the RNA. All RNA samples were standardised to a concentration of 100ng/µl. 
Total RNA was used to prepare cDNA using the miScript II RT kit (miScript Reverse Transcriptase 
Mix, 10× miScript Nucleics Mix, 5× miScript HiSpec Buffer; Qiagen, Catalog no. 218161) according 
to the manufacturer’s instructions. 
 
2.5 Quantitative PCR 
miR-146a expression was analysed using the miScript SYBR Green PCR kit (Qiagen, Catalog no. 
218073) according to the manufacturer’s instructions. The miR-146a expression assay was run in 
triplicates. Human U6 was used as the internal control. 
The comparative threshold cycle (Ct) method was used to assess the relative changes in A no-template 
control was run with the positive samples to assess the overall specificity of the reaction [27]. 
expression. 2-ΔΔCt  represents the fold change in miR-146a expression between sample groups.  
 
2.6 Western Blot Analysis 
Cytobuster™ reagent (Novagen) supplemented with protease and phosphatase inhibitors (Roche, 
05892791001 and 04906837001 respectively) was used for protein isolation. Cytobuster (200μl) was 
added to PBMCs (4°C, 10min) and centrifuged (180 x g; 4°C, 10min) to obtain a crude protein 
extract. Protein samples were quantified using the bicinchoninic acid assay and standardized to 
0.5mg/ml. Protein sample were prepared with laemlii buffer (0.5M Tris (pH 6.8), glycerol, 10% 
sodium dodecyl sulfide (SDS), 0.5% bromophenol blue, β-mercaptoethanol) and denatured at 95°C. 
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Samples (25μl) were electrophoresed on 7.5% SDS-polyacrylamide gel electrophoresis gels and 
thereafter transferred to nitrocellulose membranes using the Trans-Blot® Turbo™ Transfer system 
(BIORAD). Membranes were blocked with 5% bovine serum albumin (BSA) in Tris buffer saline 
(20mM Tris-HCl (pH 7.4), 500mM NaCl and 0.01% Tween 20 (TBST)) for 1 hour, and incubated 
with primary antibody (IRAK-1; Cell Signalling Technology 4769, TRAF-6; Cell Signalling 
Technology 8347, NF-κB; ab17742, and β-actin; ab8226, 1:1000) in 1% BSA in TBST at 4°C 
overnight. Membranes were then washed (TBST, 4× 15min) and treated with secondary antibody 
(Anti-rabbit IgG, HRP-linked; Cell Signalling Technology 4769, 1:2000) for 1 hour at room 
temperature. Membranes were washed again (TBST, 4× 15min) and protein expression was detected 
by the LumiGLO® chemiluminescent substrate system (KPL) with the Alliance 2.7 Image 
Documentation System (UViTech). Protein bands were standardised against β-actin, and analyzed 
with the Advanced Image Analysis software (UViTech v12.14). The results were expressed as mean 
relative band intensity (RBI). 
 
2.7 Statistical Analysis 
The Hardy-Weinberg equilibrium was used to test for deviation of allele/genotype frequency. All 
other statistical analysis was performed with Graphpad prism software (version 5.0). Allele and 
genotype frequencies were calculated using the Fisher’s exact and Chi-square tests respectively. The 
comparison of miR-146a expression between CAD patients and controls were done by a 
nonparametric t-test. All other calculations were done by performing a 1way ANOVA. 





Amongst the clinical parameters assessed between the groups, body mass index (BMI), hypertension, 






Table 6.1 Demographics and clinical parameters 
  
          
  Control (n=100) Cases (106) p value 
Prediabetic/Diabetic (n (%)) 39 (39) 59(58) 1.000 
Age (years) 37.5 (0.44) 37.6 (0.40) 0.856 
BMI (kg/m2) 26.5 (0.47) 28.2 (0.46) 0.011* 
Laboratory parameters 
       Total Cholesterol (mmol/L) 5.48 (0.10) 5.36 (0.18) 0.583 
    LDL (mmol/L) 3.72 (0.09) 3.42 (0.17) 0.115 
    HDL (mmol/L) 0.96 (0.03) 0.93 (0.03) 0.358 
    Triglycerides (mmol/L) 1.88 (0.18) 2.37 (0.15) 0.0399* 
    Fasting Glucose (mmol/L) 5.45 (0.16) 6.34 (0.27) 0.0054* 
    Fasting Insulin (uIU/ml) 16.34 (1.26) 16.02 (1.08) 0.850 
    HbA1c (%) 5.70 (0.10) 6.61 (0.19) <0.0001* 
    hsCRP (mg/L) 6.69 (1.12) 8.05 (1.15) 0.400 
Medication  (%) 
 
(%) 
   Statins 3 
 
84 
   Aspirin 0 
 
87 
   Beta blockers 0 
 
79 
   Nitrates 0 
 
37 
   ACE inhibitors 2  72    




The genotype distribution complied with the Hardy-Weinberg equilibrium in patients and controls 
(Chi-square p=0.7356 and p=0.8501 respectively). No significant difference was observed in 
distribution of the miR-146a genotypes between the patients and controls (p=0.9164, OR=1.025, 95% 
CI 0.6782 – 1.550; Table 6.2). The rare C allele was more frequent in CAD patients (69) than controls 
(64). 
 
Table 6.2 miR-146a rs2910164 G/C genotype and allele frequency distribution in CAD patients 
and controls 
Frequency n (%) CAD patients Controls p-value 
Genotype   *0.6320 
GG 50 (47) 45 (45)  
GC 43 (41) 46 (46)  
CC 13 (12) 9 (9)  
Allele   **0.9164 
G 143 (67) 136 (68)  
C 69 (33) 64 (32)  
 
*Chi-squared test X2=0.9176, 2 DF 
**Fisher’s exact test p=0.9164, RR=1.013 (95% CI 1.8181 – 1.254), OR=1.025 (95% CI 
0.6782 – 1.550) 
RR: Relative risk, CI: Confidence interval, OR: Odds ratio, DF: degrees of freedom 
 
Relative to the controls, CAD patients exhibited a 2.58 fold increase in miRNA-146a expression 
(p=0.3939) (Figure 6.1). CAD patients with the miR-146a rs2910164 CC genotype expressed 
significantly higher levels of miR-146a (6.25 fold increase compared to controls and CAD patients 





Figure 6.1 Fold change in miR-146a expression levels in CAD patients relative to controls 
 
 
Figure 6.2 miR-146a expression in CAD patients and controls with different genotypes ***p<0.0001 
 
Patients with the CC genotype expressed significantly lower levels of IRAK-1 (0.38±0.02; p=0.0072; 
compared to GC, Figure 6.3) and TRAF-6 (0.44±0.02; p=0.0146; compared to GC and GG, Figure 
6.4). These patients also expressed the lowest levels of NF-κB compared to the other genotypes, 


















































Figure 6.3 IRAK-1 expression in CAD patients (**p=0.0072) and controls 
 











































Figure 6.5 NF-κB expression in CAD patients and controls 
 
CAD patients and controls with the CC genotype presented with the lowest mean hsCRP levels 
compared to the other genotypes (6.53±1.47 and 4.23±1.17 mg/L respectively). However this did not 
reach statistical significance (p=0.7989 for CAD patients and p=0.9683 for controls, Table 6.3). 
 
Table 6.3 Mean hsCRP levels (mg/L) between genotypes in CAD patients and controls 
 CAD patients Controls 
Genotype Mean hsCRP levels (± standard deviation) 
GG 7.49±1.77 7.67±2.22 
GC 9.01±1.88 6.17±1.04 
CC 6.53±1.47 4.23±1.17 































The present study investigated the possible association between the miR-146a rs2910164 and miR-
146a expression in young South African Indian CAD patients. 
CAD patients with the miR-146a rs2910164 CC genotype expressed significantly higher levels of 
miR-146a (6.25 fold increase compared to controls and CAD patients with the reference GG 
genotype; p<0.0001) and significantly lower levels of IRAK-1 (0.38±0.04; p=0.0072; compared to 
GC) and TRAF-6 (0.44±0.05; p=0.0146; compared to GC and GG). Furthermore, these patients also 
expressed the lowest levels of NF-κB and hsCRP compared to the other genotypes, although this did 
not reach statistical significance. We propose a possible mechanism for the observed phenomenon. 
IRAK-1 and TRAF-6 are both involved in the MyD88-dependent branch of the TIR signalling 
pathway [19, 28]. MyD88 is important for the activation of inflammatory cytokines triggered by all 
TIRs. Upon stimulation, MyD88 recruits IRAK-1 to the receptor. IRAK-1 is phosphorylated and 
complexed with TRAF-6, and together they dissociate from the receptor. A series of further 
interactions lead to phosphorylation of IκB, thereby releasing the transcription factor NF-κB into the 
nucleus and allowing the induction of inflammatory genes [28]. 
IRAK-1 and TRAF-6 are known targets of miR-146a [18]. The promoter region of miR-146a contains 
several binding sites for the transcription factor NF-κB, and the induced expression of miR-146a 
occurs in a NF-κB-dependent manner [7].  
miR-146a inhibits IRAK-1 and TRAF-6 expression through negative feedback regulation (Figure 7) 
[7, 29]. Therefore, higher levels of miR-146a levels lead to increased inhibition of IRAK-1 and 
TRAF-6, causing decreased levels of pro-inflammatory cytokines such as IL-1,  IL-6, IL-8, TNF-α 
[29]. These cytokines are known regulators of CRP [30], and a decrease in their levels consequently 





Figure 6.7 The role of miRNA-146a in the inflammatory response through a negative feedback 
mechanism (Author’s own work) 
 
Decreased hsCRP levels observed in CAD patients with the CC genotype may be as a result of them 
expressing significantly higher levels of miR-146a, increased binding to and inhibition of IRAK-1 and 
TRAF-6. 
In contrast to our study, a previous investigation of the miR-146a rs2910164 in hepatocellular 
carcinoma by Xu et al. observed an increased production of miR-146a associated with the GG 
genotype [9]. In 2008, Shen et al. observed an increase in miR-146a expression in breast/ovarian 
cancer patients with the variant C allele [31]. However, neither of these studies investigated the target 
molecules of miR-146a and downstream effects of dysregulated miR-146a. This is the first study to 
investigate the miR-146a rs2910164 and its influence on miR-146a and miR-146a target molecule 
expression in young South African Indian CAD patients. 
Since high levels of pro-inflammatory cytokines and CRP contribute to the chronic inflammation seen 
in CAD, the CC genotype serves a protective function by increasing miR-146a levels and reducing 
inflammation. Our study suggests miR-146a as an important modulator of the inflammatory response. 
Based on these findings, miR-146a could serve as a potential target in therapeutic interventions 
towards lowering inflammation and alleviating the complications in CAD. 
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Study limitations include sample size, lack of exclusion criteria on BMI, hypertension, diabetes, and 
effects of medication. The involvement of additional SNPs and/or regulatory molecules which are yet 
to be discovered may be a confounding factor in our study. A follow up study with larger patient 
populations would provide further clarification. 
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Indian populations throughout the world show an unusually high prevalence of early-onset CAD 
compared to other ethnicities (Rajeshwari, Nicklas et al. 2005; Sharma M 2005; Aggarwal, Aggarwal 
et al. 2012; Khan 2013). South African Indians have a much higher mortality rate due to CAD 
compared to Black South Africans (Norman, Schneider et al. 2006). Until recently, genetic and 
epigenetic studies in CAD in developing countries such as SA have resulted in minimal literature 
being available. This study is the first to investigate genetic and miRNA polymorphisms in SA 
Indians with CAD. We assessed SNPs in four candidate genes; MTHFR, SIRT1, miR-146a, and miR-
499; all of which have been implicated in chronic inflammatory diseases such as CAD, but have never 
been investigated in SA Indians. 
The MTHFR gene encodes for a protein with important enzymatic functions in folate and methyl-
group metabolism (Botezatu, Socolov et al. 2013). The enzyme irreversibly catalyses the reduction of 
5′,10′-methylenetetrahydrofolate to 5′-methyltetrahydrofolate; a major form of circulating folate, and 
the precursor of SAM - the universal methyl donor for several biological methylation reactions 
(Kluijtmans and Whitehead 2001; Friso, Girelli et al. 2002). The common MTHFR C677T SNP has 
been widely investigated and is known to affect enzyme activity (Vasisht, Gulati et al. 2002; Oyama, 
Kawakami et al. 2004; Sastry, Golla et al. 2011; Wang, Pei et al. 2012).  
An important finding in this study was the significantly higher prevalence of the MTHFR 677 variant 
allele in CAD patients compared with Indian controls. In addition, it was also observed that Indian 
controls presented with a higher frequency of the variant allele when compared to Black controls. 
This is of significance since the variant allele has been associated with increased levels of Hcy, an 
independent risk factor for CAD (Mehlig, Leander et al. 2013). The higher frequency of the MTHFR 
677 variant allele in SA Indians may be a contributing factor to the higher risk profile for the 
development of early-onset CAD in this population. In Black South Africans, the low prevalence of 
the MTHFR 677 variant allele may confer protection against CAD. 
Further, the results of this study support the findings of a recent study that investigated the frequency 
of the MTHFR C677T SNP and its effect on homocysteine levels in another cohort of Black South 
Africans. It was observed that 15.2%, 0.8%, and 84% of the study population harboured the MTHFR 
677 CT, TT, and CC genotypes respectively (Nienaber-Rousseau, Ellis et al. 2013). Subjects with the 
MTHFR 677 homozygous variant genotype had the highest Hcy levels while carriers of the CC 
genotype had the lowest Hcy levels. The low incidence of the MTHFR 677 TT genotype amongst 
Black South Africans was speculated to play a protective role in this population against risk of Hcy-
associated disease (Nienaber-Rousseau, Ellis et al. 2013). The results of this study and that of 
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Nienaber-Rousseau et al. 2013 show a consistency with regard to the low prevalence of the MTHFR 
TT genotype in Black South Africans. 
Like MTHFR, SIRT1 has also been identified as a candidate that affects the epigenetic mechanisms of 
CAD (Cui, Wang et al. 2012). Sirtuin 1 is a class III histone deacetylase that regulates several 
important metabolic and physiological pathways. In addition to targeting histones, numerous non-
histone SIRT1 target proteins such as adenosine monophosphate activated protein kinase (AMPK), 
FoxO, NF-κB, eNOS, p53, peroxisome proliferator-activated receptor-gamma (PPAR-γ) and its 
coactivator PGC-1α, have been identified (Tomé-Carneiro, Larrosa et al. 2013; Ma and Li 2015). In 
the cardiovascular system, SIRT1 has been recognised as a key regulator of vascular endothelial 
homeostasis, and also regulates angiogenesis, endothelial senescence, and dysfunction. It serves a 
critical role in RCT and reduces the risk of CVD (Ma and Li 2015).  
This study compared the role of two SIRT1 SNPs, rs1467568 and rs789583, in SA Indians with CAD 
to Indian and Black controls. No difference was observed in the distribution of SIRT1 SNPs between 
CAD patients and control groups. The variant allele was more frequent in Indian controls compared to 
Black controls, but this did not reach statistical significance. Previous studies have shown that SIRT1 
SNPs are associated with BMI and obesity, blood pressure, dyslipidaemia, inflammation, and 
coronary artery calcification (Peeters, Beckers et al. 2008; Zillikens, van Meurs et al. 2009; 
Shimoyama, Suzuki et al. 2011; Botden, Zillikens et al. 2012; Shimoyama, Mitsuda et al. 2012). This 
study observed no association between the SIRT1 SNPs and BMI, total cholesterol, LDL, HDL, 
triglycerides, fasting glucose, fasting insulin, HbA1c, hsCRP, or IL-6 in CAD patients and control 
groups.  
The frequency of rs7895833 and rs1467568 vary among different ethnicities, and may be a reason for 
differing disease patterns among populations. The frequency of the rs7895833 A allele was relatively 
low (0.29) in Japanese compared to Dutch, Turkish and Caucasians who had similar allele frequencies 
(0.80, 0.85, and 0.80 respectively) (Zillikens, van Meurs et al. 2009; Maeda, Koya et al. 2011; 
Shimoyama, Suzuki et al. 2011) The A allele of rs1467568 showed marked difference in frequency 
between the European (0.25) and Japanese (0.84) (Maeda, Koya et al. 2011). To date, there have been 
no published studies investigating rs7895833 and rs1467568 in Indians with CAD to validate the 
findings of the present study.  
It’s important to note that metabolic effects of SIRT1reported in literature have mainly been observed 
under conditions of calorie restriction (CR) (Cohen 2004; Chen, Bruno et al. 2008; Naqvi, Hoffman et 
al. 2010; Botden, Zillikens et al. 2012), while the present study population was not subjected to CR. It 
is possible that associations between SIRT1 variants and CAD risk can only be found when 




A more recent advance in epigenetic research has been the study of miRNAs. These small noncoding 
RNA molecules negatively regulate target gene expression by inhibiting mRNA translation or 
promoting mRNA degradation (Jamaluddin, Weakly et al. 2011). MicroRNA polymorphisms were 
shown to affect miRNA expression and/or miRNA-mRNA interaction, and have been associated with 
human diseases (Chen, Song et al. 2008; Ardekani and Naeini 2010; Li, Chen et al. 2010). Since CAD 
is a chronic inflammatory disease, SNPs in inflammatory associated miRNAs were of interest in this 
study. Two such SNPs, rs3746444 and rs2010164, in miR-499 and miR-146a respectively were 
assessed. 
MicroRNA-499 plays a critical role in inflammation by targeting several cytokines that play a role in 
the pathogenesis of CAD. These targets include IL-2, IL-2β, IL-6, IL-17, IL-17Rβ, IL-18, IL-21, and 
IL-23a (Yang, Chen et al. 2012). The variant (G) allele of a common miR-499 SNP, rs3746444, 
results in a less stable secondary structure than the ancestral (A) allele and affects the binding to target 
mRNAs (Akkız, Bayram et al. 2011). 
The miR-499 variant allele was more frequent in CAD patients compared to Indian controls, almost 
reaching statistical significance. The total Indian group presented with a higher frequency of the 
rs3746444 G allele compared to the total Black population but this was not statistically significant. 
Since miR-499 targets inflammatory cytokines, the levels of IL-6 and hsCRP were then assessed. A 
trend was observed in CAD patients harboring the variant genotypes having elevated IL-6 and hsCRP 
compared to those with the wild type genotypes. The change from A-to-G in the seed sequence of 
miR-499 may interfere with its binding to and interaction with targets such as IL-6. CRP is under the 
direct influence of IL-6, which may explain why we observed increased levels of both (IL-6 and 
hsCRP) in patients with the variant genotype. 
A comprehensive literature search revealed only two published studies regarding miR-499 and CAD. 
Of these two studies, Zhi et al found that the GG genotype was associated with a 3.23-fold increased 
risk of CAD in a Chinese Han population (Zhi, Wang et al. 2012). In contrast, Xiong et al found no 
association between rs3746444 and CAD in another Chinese Han population (Xiong, Cho et al. 2014). 
Our findings may implicate miR-499 as a target in the regulation of inflammation in CAD, but a 
larger follow up study investigating the functional significance of this miR-499 SNP may provide 
additional clarification. 
A major finding in this study was the role of a common miR-146a SNP, rs rs2910164, in CAD 
patients. The frequency of genotypes was similar between CAD patients and Indian controls. 
Interestingly, a significant 6.25-fold increase in miR-146a levels was observed in CAD patients with 
the CC genotype relative to controls and patients with the wildtype variant. We then investigated the 
targets of miR-146a, IRAK-1 and TRAF-6, and found that the expression of these targets was 
significantly decreased in CAD patients with the CC genotype. Both miR-146a targets act 
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downstream of the NF-κB-dependant TIR signalling pathway (Chatzikyriakidou, Voulgari et al. 
2010). The lowest levels of NF-κB were found in patients with the homozygous C allele compared to 
the heterozygous GC and wildtype variants. In addition, these patients (CC genotype) also had the 
lowest hsCRP compared to those with the other genotypes. 
Since high levels of pro-inflammatory cytokines contribute to the chronic inflammation seen in CAD, 
the CC genotype serves a protective function by increasing miR-146a levels and reducing 
inflammation. The results of this study implicate a role for miR-146a in TIR signalling via a negative 
feedback mechanism involving the attenuation of NF-κB by downregulation of IRAK-1 and TRAF-6. 
These findings suggest miR-146a as a target for therapy towards lowering inflammation in CAD 
patients. 
There have been substantial advances recently in elucidating the genetic background of many 
complex diseases, including CAD but much, if not most, is yet to be discovered – especially in the 
Indian population. Identifying individuals at risk for the development of CAD is integral for primary 
prevention of the disease. Genetics in combination with clinical parameters may help us to understand 
pathogenesis of disease and possibly will improve the prediction of CAD. 
Although recruitment numbers were adequate to detect statistical differences, follow-up studies with a 
larger sample size may provide further clarification. Nevertheless, the findings presented provide 
improved insight into how underlying genetic and epigenetic factors influence CAD in SA Indians. 
Hopefully, such insight may be translated into future interventions capable of providing CAD patients 
in general, a longer and healthier life. 
Taken together, the findings of this study provide insight into four candidate genes for CAD in young 
South African Indians and Blacks. This was the first investigation of genetic (MTHFR and SIRT1) 
and epigenetic (miR-146a and miR-499) polymorphisms in young SA Indians with CAD. The 
frequency of variant alleles was predominant in SA Indians and may predispose towards the 
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Polymerase Chain Reaction 
The principle of polymerase chain reaction (PCR) is based on the exponential amplification of a 
particular DNA sequence using specially designed primers, deoxynucleoside triphosphates (dNTP), 
DNA polymerase (usually derived from Thermus aquaticus (Taq)), buffer solution, magnesium 
chloride (MgCl2), and a DNA template (Figure 1). The process relies on thermal cycling, consisting of 
repeated heating cooling cycles, and involves three major steps i.e. denaturation, annealing, and 
extension.  
Denaturation occurs at approximately 95°C. Double-stranded DNA (dsDNA) is melted, forming 
single-stranded DNA templates. Temperature is lowered (between 55-60°C) and the primers are 
allowed to anneal to the 3’ ends of each single-stranded DNA template. Extension of DNA occurs at 
72°C, the optimum temperature at which Taq polymerase functions to extend the target DNA 
sequence by the addition of dNTPs from the 3’ end of the annealed primer. 
The steps are repeated for 20 to 40 cycles, and at the end of each cycle DNA is amplified two-fold. 
The PCR product is run on an agarose gel by means of electrophoresis. Visualization is enabled by 
staining with ethidium bromide and UV light exposure. A DNA ladder (also known as a molecular 
weight marker) may be run alongside to determine the size of the PCR product.  
 
Figure 1 The Polymerase Chain Reaction (Author’s own work) 
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Optimisation of Polymerase Chain Reaction  
Major components of the PCR (primers, MgCl2 and GoTaq DNA polymerase) were optimised to 
ensure an efficient and specific amplification process. Primer sets were optimised first by varying the 
concentrations between 10 and 100 ρmol, while all other components were kept at a standard 
concentration. Once the PCR was completed, amplicons were verified by electrophoresis (150 V; 50 
min) on agarose gel (1.8%, 0.5 mg/ml ethidium bromide) and visualized by ultra violet (UV) light and 
digitally photographed using a gel documentation system (Uvitech Alliance 2.7).  
The reaction that had the least non-specific binding, and produced a clear band of the target DNA was 
chosen. This concentration was used in the optimisation of MgCl2. Finally Taq polymerase was 
optimised using the optimal primer and MgCl2 concentrations. MgCl2 and Taq polymerase 
concentrations ranged from 0.5 to 3 mM and 0.1 to 0.5 units (U) respectively.  
Since no single protocol is appropriate to all situations, each new PCR application required 
optimisation. Optimised concentrations for each PCR component for each SNP investigated can be 
found in below (Table1 – Table 3): 
 
Table 1 miR-146a G/C SNP (rs2010164) 
Optimised Reaction 
Conditions 
(Reaction volume = 30µl) 
Optimised concentrations 
DNA template 10 ng/µl 
MgCl2 2.5 mmol 
Taq polymerase 0.2U 
dNTP 200 µM of each 
Forward primer (100 ρmol) 40 ρmol 
Reverse primer (100 ρmol) 40 ρmol 
5× Green GoTaq® Flexi Buffer 1× 
Nuclease-free H2O  
Optimised Cycling Conditions 
(30 cycles) 
 
Denaturation 94°C for 10 minutes 
 94°C for 30 seconds 
Annealing 65°C for 30 seconds 




Table 2 MTHFR C/T SNP (rs1801133) 
Optimised Reaction 
Conditions 
(Reaction volume = 25µl) 
Optimised concentrations 
DNA template 10 ng/µl 
MgCl2 2.5 mmol 
Taq polymerase 0.2U 
dNTP 200 µM of each 
Forward primer (100 ρmol) 20 ρmol 
Reverse primer (100 ρmol) 20 ρmol 
5× Green GoTaq® Flexi Buffer 1× 
Nuclease-free H2O  
Optimised Cycling Conditions 
(35 cycles) 
 
Denaturation 95°C for 5 minutes 
 95°C for 1 minute 
Annealing 59°C for 1 minute 
Extension 72°C for 2 minutes 













Table 3 miR-499 G/C SNP (rs3746444) 
Optimised Reaction 
Conditions 
(Reaction volume = 25µl) 
Optimised concentrations 
DNA template 10 ng/µl 
MgCl2 2.5 mmol 
Taq polymerase 0.5Unit 
dNTP 200 µM of each 
Forward primer (100 ρmol) 40 ρmol 
Reverse primer (100 ρmol) 40 ρmol 
5× Green GoTaq® Flexi Buffer 1× 
Nuclease-free H2O  
Optimised Cycling Conditions 
(34 cycles) 
 
Denaturation 94°C for 5 minutes 
 94°C for 1 minute 
Annealing 59°C for 30 seconds 
Extension 72°C for 2 minutes 















Restriction Fragment Length Polymorphism 
Restriction fragment length polymorphism (RFLP) is a method that exploits variations in homologous 
DNA sequences. Restriction enzymes recognize specific nucleotide sequences on a DNA strand and 
cleave at precise points. Following PCR, the PCR products are digested by a specific restriction 
enzyme to analyse the presence of a polymorphism. The consensus sequences and cleavage sites for 
each enzyme is unique, shown below (Table 4 – Table 6): 
 
Table 4 Consensus sequence and cleavage site (arrows) for Sac I: 
Restriction Enzyme Consensus Sequence 
Sac I 5’…G A G C T ↓ C… 3’ 
3’…C ↑ T C G A G… 5’ 
 
Table 5 Consensus sequence and cleavage site (arrows) for Hinf I: 
Restriction Enzyme Consensus Sequence 
Hinf I 5’…G ↓ A N T    C… 3’ 
3’…C    T  N A ↑G… 5’ 
 
Table 6 Consensus sequence and cleavage site (arrows) for Bcl I: 
Restriction Enzyme Consensus Sequence 
Bcl I 5’…T ↓ G A T C    A… 3’ 





Overnight digestion was performed (at 37°C for Sac I and Hinf I; and at 55°C for Bcl I) in 25μL 
(15μL PCR product, 4.5μL enzyme-specific Buffer and 0.5μL (5U) restriction enzyme). Restriction 




Figure 2 Diagrammatic representations of PCR-RFLP product sizes and corresponding genotypes for 











Synthesis of cDNA 
Total RNA was used to prepare copy DNA (cDNA) using the miScript II RT kit (miScript Reverse 
Transcriptase Mix, 10× miScript Nucleics Mix, 5× miScript HiSpec Buffer; Qiagen, Catalog no. 
218161) following the manufacturer’s instructions (Figure 3). Components were added according to 
Table below (Table 7). 
Table 7 Components of reverse transcription reaction 
Component Volume/reaction 
5× miScript HiSpec Buffer 4µl 
10× miScript Nucleics Mix 2µl 
RNase-free water 10µl 
miScript Reverse Transcriptase Mix 2µl 
Template RNA 2µl 
Total volume 20µl 
 
 




Quantitative Polymerase Chain Reaction 
Quantitative PCR (qPCR) is a technique based on the general principle of PCR and is used to 
simultaneously amplify and quantify the target DNA. Amplified DNA is detected as the reaction 
progresses in real-time, and hence qPCR is also known as real-time PCR. This method does not 
require the end-detection of the product as in the case of traditional PCR where the product is run on a 
gel via electrophoresis. Quantitative PCR incorporates SYBR Green, a dye used as a nucleic acid stain 
that binds to dsDNA, which emits fluorescent intensity proportional to the amount of dsDNA.  
Quantitative PCR was used to determine the levels of miR-146a for each genotype in CAD patients 
and controls. A reaction mix for detection of mature miR-146a was prepared and subjected to the 
cycling conditions as follows (Table 8 and Table 9): 
 
Table 8 Reaction mix for detection of mature miR-146a 
Component Volume/reaction 
2× QuantiTect SYBR Green PCR Master Mix 12.5 µl 
10× miScript Universal Primer Assay 2.5 µl 
10× miScript Primer Assay 2.5 µl 
RNase-free water 5.5 µl 
Template cDNA 2 µl 
Total volume 25 µl 
 
Table 9 Cycling conditions for the quantitative analysis of mature miR-146a 
Step Time Temperature 
Initial activation step 15 min 95°C 
3-step cycling:   
Denaturation 15 sec 94°C 
Annealing 30 sec 55°C 
Extension 30 sec 70°C 






Figure 4 miR-46a levels in each miR-146a rs2910164 genotype in CAD patients. The CC genotype 
had the highest miR-146a expression, and therefore the lowest CT value compared to the other 
genotypes (red: GG, green: GC, blue: CC) 
 
Analysis of Quantitative Polymerase Chain Reaction Results 
The comparative threshold cycle (Ct) method was used to assess the relative changes in miR-146a 
expression. 2-∆∆Ct  represents the fold change in miR-146a expression between sample groups (Figure 
4). A negative control without a genomic DNA template was run with the positive samples to assess 
the overall specificity of the reaction (Livak and Schmittgen 2001). The figure below is a table 






Figure 5 An example of relative quantification using the comparative threshold cycle (Ct) method 




















Cytobuster™ reagent (Novagen) supplemented with protease and phosphatase inhibitors (Roche, 
05892791001 and 04906837001 respectively) was used for protein isolation. Cytobuster (200μl) was 
added to PBMCs (4°C, 10 min) and centrifuged (180 x g; 4°C, 10 min) to obtain a crude protein 
extract. Protein samples were quantified using the bicinchoninic acid (BCA) assay. 
 
The Bicinchoninic Acid Assay 
The bicinchoninic acid assay (BCA) is based on the reduction of Cu2+ to Cu+ by protein in an alkaline 
medium (the biuret reaction). The Cu+ is then detected by reaction with BCA, and results in the 
development of a purple-colored product with maximum absorbance at 562nm. 
Serial dilutions of Bovine serum albumin (BSA) were prepared (0mg/ml, 0.2mg/ml, 0.4mg/ml, 
0.6mg/ml, 0.8mg/ml, and 1mg/ml) to serve as standard concentrations (Figure 6). 25µl of each sample 
and the relevant standards were added to appropriately labelled wells, followed by the addition of 
200µl BCA working solution (4µl CuSO4 and 198µl BCA) into each well. The plate was incubated at 
37°C for 30 minutes. Absorbance was read at 562nm using a spectrophotometer. Concentration of 
each protein sample was calculated from a standard curve constructed using the absorbencies of the 







Figure 6 Protein standardisation by the BCA 
 
Preparation of samples for Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 
Laemlii sample buffer (0.5M Tris (pH 6.8), glycerol, 10%SDS, 0.5% bromophenol blue, β-
mercaptoethanol, dH2O) was prepared and added to protein samples (1:1). Samples were boiled at 
95°C for 5 minutes to activate the β-mercaptoethanol and SDS to allow for reduction and unfolding of 
proteins. 
 
Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis and Western Blot 
Western blotting is a technique used to detect and analyse proteins. Proteins are separated on two 
types of agarose gel (stacking and resolving) via electrophoresis based on their molecular weight. The 
results are then transferred onto a membrane and blocked with 1% BSA to prevent nonspecific 
binding of the antibodies. The membrane is incubated with primary and corresponding secondary 
antibodies (usually labelled with horseradish peroxidase) which are specific to the protein of interest. 
The unbound antibody is washed off, leaving only the bound antibody. Detection of the protein by 
chemiluminescence is enabled by the oxidation of luminol (in the detection reagent) in the presence of 
peroxide, resulting in light emission. 
Samples (25μl) were electrophoresed on 7.5% SDS-PAGE gels and thereafter transferred to 
nitrocellulose membranes using the Trans-Blot® Turbo™ Transfer system (BIORAD). Membranes 
y = 0.1032x - 0.1197 














were blocked with 5% BSA in Tris buffer saline (20mM Tris-HCl (pH 7.4), 500mM NaCl and 0.01% 
Tween 20 (TBST)) for 1 hour, and incubated with primary antibody (IRAK-1; Cell Signalling 
Technology 4769, TRAF-6; Cell Signalling Technology 8347, NF-κB; ab17742, and β-actin; ab8226, 
1:1000) in 1% BSA in TBST at 4°C overnight. Membranes were then washed (TBST, 4× 15 min) and 
treated with secondary antibody (Anti-rabbit IgG, HRP-linked; Cell Signalling Technology 4769, 
1:2000) for 1 hour at room temperature. Membranes were washed again (TBST, 4× 15min) and 
protein expression was detected by the LumiGLO® chemiluminescent substrate system (KPL) with 
the Alliance 2.7 Image Documentation System (UViTech).  
 
Analysis of Western Blot 
Protein bands were standardised against β-actin, and analyzed with the UViBand Advanced Image 



















Interleukin-6 Enzyme-linked immunosorbent assay 
Human IL-6 enzyme-linked immunosorbent assay (ELISA) Kit II (BD OptEIA™) was used to 
measure the IL-6 serum levels of patients and controls. As per user manual, ELISA diluent (12ml 
buffered protein base, 0.09% sodium azide) was added into a 96 well microtitre plate coated with anti-
human IL-6 monoclonal antibody. A serial two fold dilution ranging from 0pg/ml to 250pg/ml was 
prepared (Table 10). Standards and samples were added into appropriate wells. Following incubation 
(2h, RT) wells were rinsed with wash buffer (1× detergent solution with ProClin™-150). Working 
detector (containing Streptavidin-horseradish peroxide and Biotinylated anti-human IL-6 monoclonal 
antibody) was added into each well and incubated (1h, RT, dark). Wells were rinsed with wash buffer, 
seven times, followed by the addition of TMB One-Step Substrate Reagent (3,3’,5,5’-
tetramethylbenzidine) and incubated (30min, RT, dark). Following incubation, stop solution (1M 
phosphoric acid) was added, and absorbance measured at450nm (reference: 570nm) with a microplate 
reader (Bio-Tek μQuant, United States). Serum concentrations of IL-6 were calculated by 
extrapolation from the standard curve (Figure 7). 
 
Table 10 Preparation of samples of known concentration for the IL-6 ELISA 
Standard concentration Volume IL-6 Volume Distilled Water 
150 ρmol 50.0 µl 50.00 µl 
75 ρmol 25.0 µl 45.00 µl 
37.5 ρmol 12.5 µl 87.50 µl 
18.8 ρmol 6.52 µl 93.75 µl 
9.4 ρmol 3.13 µl 96.87 µl 
4.7 ρmol 1.56 µl 98.44 µl 






Figure 7 Standard curve derived from the IL-6 standards 
Standard IL-6 concentrations were prepared and used to create the standard curve above. The curve 
was extrapolated and the equation (y=0.002x + 0.049) used to determine the serum IL-6 















TaqMan® SNP Genotyping Assay 
Following the manufacturer’s protocol, TaqMan® SNP Predesigned Genotyping Assay (Life 
Technologies, Cat #4351379) was used to genotype all subjects for SIRT1 rs1467568 and rs7895833. 
The TaqMan Predesigned Genotyping Assay contains two primers for amplifying the sequence of 
interest and two TaqMan® minor-groove binding (MGB) probes for detecting alleles. The presence of 
two probe pairs in each reaction allows genotyping of the two possible variant alleles at the SNP site 
in a DNA target sequence. The genotyping assay determines the presence or absence of a SNP based 
on the change in fluorescence of the dyes associated with the probes. The TaqMan® MGB Probes 
consist of target-specific oligonucleotides with a reporter dye at the 5´ end of each probe: One VIC®-
labelled probe to detect Allele 1 sequence (A-allele in the case of rs1467568 and rs7895833) and one 
FAM™-labelled probe to detect Allele 2 sequence (G-allele in the case of rs1467568 and rs7895833). 
Fluorescence signals for both dyes indicate heterozygosity for allele 1-allele 2 (AG). 
A final reaction mixture consisted of 40× TaqMan® Predesigned Genotyping Assay, 2× TaqMan® 
Genotyping Master Mix, nuclease-free water, and a 10ng genomic DNA template. The experiment 
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